Methods and systems for detecting copy number alterations
A copy number grid model overlays coverage ratios and allele frequencies to enhance the visualization and interpretation of genomic data, addressing the challenges in discerning copy number changes and improving the accuracy of CNA detection.
Patent Information
- Application Number
- JP2024520589
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-08
- Filing Date
- 2022-10-07
- Publication Date
- 2024-11-13
Smart Images

Figure 2024541815000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 253,972, filed October 8, 2021, which is incorporated by reference herein in its entirety.
[0002] The present disclosure relates to methods and systems for analyzing genomic profiling data, and more particularly, to methods and systems for calling copy number variations using genomic profiling. [Background technology]
[0003] Structural variants (SVs) are large-scale genomic changes that typically involve changes in length of at least 50 base pairs (bp) (Mahmoud, et al. (2019), “Structural variants calling: the long and the short of it”, Genome Biology 20:246). These large-scale genomic changes are classified as deletions, duplications, inversions, insertions, and translocations, and describe different combinations of DNA gains, losses, and rearrangements.
[0004] Abnormal chromosomal imbalances, commonly referred to as chromosomal aneuploidies, often occur during cell reproduction where DNA repair mechanisms are inadequately monitoring and correcting mistakes. Chromosomal aneuploidies can be a sign of disease in germline cells, but in somatic cells, copy number alterations (CNAs) are often associated with tumorigenesis and may identify key genetic drivers, leading to increased population pressure toward genetic changes that promote proliferation. Thus, metastatic cancers generally show increased chromosomal aneuploidies that affect genetic pathways that correct either copy errors or genes that promote cell proliferation.
[0005] Typical representations of data associated with copy number analysis, i.e. allele frequencies or coverage ratios, are generally genomically sorted and involve ratio transformation to log2(R). Often, allele frequency plots are collapsed so that only minor alleles are shown. Because coverage is preserved, minor and major allele frequencies are redundant and there is no loss of information in this representation. After the model is fitted, it is customary to then overlay these copy number states on top of the predicted ratios and allele frequencies. Coverage ratio plots generally show the directionality associated with copy number events. If amplification occurs, the coverage ratio increases. If deletion occurs, the coverage ratio decreases. Amplifications and deletions are more difficult to interpret from allele frequency plots. These representations are intuitive because targets are genomically sorted and observations are plotted as a function of this sorting, but it can often be difficult to visually identify how good the copy number state and the state that corresponds to both the allele frequency and coverage ratio are. Summary of the Invention
[0006] Described herein are methods and systems for calling copy number alterations (CNAs), including methods and systems for fitting a grid-based copy number model (i.e., a "copy number grid model") to sequence read data. Advantageously, fitting a copy number grid model to sequence read data allows for display of the data, making it more efficient to interpret the data and call copy number states or copy number alterations, which are often difficult to call accurately. That is, the copy number grid model provides visualization of data associated with coverage ratios and allele frequencies, and their associated errors, on the same graph, while simultaneously overlaying predicted copy number states for a more complete presentation. The resulting overlay display facilitates manual calling of copy numbers for genomic segments or loci, or manual confirmation of calls for genomic segments or loci (e.g., calls made by an automated process).
[0007] In some embodiments, a method for calling copy number alterations (CNAs) includes providing a plurality of nucleic acid molecules obtained from a sample from a subject; ligating one or more adaptors onto one or more nucleic acid molecules from the plurality of nucleic acid molecules; amplifying one or more ligated nucleic acid molecules from the plurality of nucleic acid molecules; capturing an amplified nucleic acid molecule from the amplified nucleic acid molecules; sequencing the captured nucleic acid molecules with a sequencer to obtain a plurality of sequence reads representative of the captured nucleic acid molecules, thereby generating sequence read data for a genome of the sample; receiving the sequence read data with one or more processors; generating minor allele coverage ratios and major allele coverage ratios for a plurality of loci using the one or more processors; The method includes: segmenting a genome into a plurality of genome segments; generating, using one or more processors, copy number grid model input data comprising (i) a difference between a major allele coverage ratio and a minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio, for loci among the plurality of loci; fitting, using one or more processors, a plurality of copy number grid models comprising allowed copy number states to the copy number grid model input data; selecting, using one or more processors, a selected copy number grid model from the plurality of copy number grid models; and assigning, using one or more processors, copy number states for at least a portion of the plurality of genome segments based on the selected copy number grid model.
[0008] In some embodiments, the one or more adaptors comprise an amplification primer, a flow cell adaptor sequence, a substrate adaptor sequence, or a sample index sequence.
[0009] In some embodiments, the captured nucleic acid molecules are captured from the amplified nucleic acid molecules by hybridization to one or more bait molecules, in some embodiments, the one or more bait molecules comprise one or more nucleic acid molecules, each nucleic acid molecule comprising a region complementary to a region of the captured nucleic acid molecule.
[0010] In some embodiments, amplifying the nucleic acid molecule comprises performing a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique.
[0011] In some embodiments, the sequencing comprises using massively parallel sequencing (MPS) technology, whole genome sequencing (WGS), whole exome sequencing, targeted sequencing, direct sequencing, or Sanger sequencing technology. For example, in some embodiments, the sequencing comprises massively parallel sequencing, and the massively parallel sequencing technology comprises next-generation sequencing (NGS). In some embodiments, the sequencing comprises a next-generation sequencer.
[0012] In some embodiments, a method for calling copy number alterations (CNAs) includes receiving, with one or more processors, sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject; generating, using the one or more processors, minor allele coverage ratios and major allele coverage ratios for the plurality of loci; segmenting, using the one or more processors, a genome into a plurality of genome segments; generating, using the one or more processors, copy number grid model input data comprising (i) a difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio, for loci among the plurality of loci; fitting, using the one or more processors, a plurality of copy number grid models comprising allowed copy number states to the copy number grid model input data; selecting, using the one or more processors, a selected copy number grid model from the plurality of copy number grid models; and assigning, using the one or more processors, copy number states for at least a portion of the plurality of genome segments based on the selected copy number grid model.
[0013] In an embodiment of any of the above methods, segmentation is based on minor allele coverage ratio, major allele coverage ratio, or total coverage ratio.
[0014] In an embodiment of any of the above methods, selecting a copy number grid model from the plurality of copy number grid models comprises: determining, for each genome segment, a distribution of copy number grid model input data; identifying, for each genome segment, a distance between the distribution and a nearest copy number state; and determining an overall model fit score based on an average distance across the plurality of genome segments.
[0015] In an embodiment of any of the above methods, different copy number grid models in the plurality of copy number grid models are initialized using different initial tumor purity estimates and tumor ploidy estimates.
[0016] In an embodiment of any of the above methods, fitting the multiple copy number grid models to the copy number grid model input data includes, for each copy number grid model, fitting allowed copy number states of the copy number grid model to the copy number grid model input data based on an initial tumor purity estimate and an initial tumor ploidy estimate; iteratively assigning preliminary copy numbers to each genome segment of the multiple genome segments; determining an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignments; and re-fitting the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate.
[0017] In embodiments of any of the above methods, the initial tumor purity is constrained by a preselected lower tumor purity limit and a preselected upper tumor purity limit. In some embodiments, the preselected lower tumor purity limit is 0 and the preselected upper tumor purity limit is 1.
[0018] In some embodiments of any of the above methods, the initial tumor ploidy is constrained by a preselected tumor ploidy lower limit. In some embodiments, the preselected tumor ploidy lower limit is about 1.1 to about 1.5. In some embodiments, the initial tumor ploidy is constrained by a preselected tumor ploidy upper limit. In some embodiments, the preselected tumor ploidy lower limit is about 6 to about 10.
[0019] In embodiments of any of the above methods, the assigned copy number state for each of the plurality of genome segments is a total copy number count for the genome segment, a minor allele copy number count for the genome segment, or a major allele copy number count for the genome segment.
[0020] In an embodiment of any of the above methods, the segmentation step is performed using a circular binary segmentation (CBS) method, a maximum likelihood method, a hidden Markov chain method, a walking Markov method, a Bayesian method, a long-range correlation method, or a change-point method. In some embodiments, the segmentation step is performed using a change-point method, and the change-point method is a pruned exact linear time (PELT) method.
[0021] In some embodiments of any of the above methods, the method further comprises overlaying the selected copy number grid model and the copy number grid model input data to generate an overlay. The overlay may then be displayed. In some embodiments, the overlay is displayed using an electronic display.
[0022] In embodiments of any of the above methods, the method further comprises calling copy number alterations for one or more loci or one or more genomic segments based on one or more assigned copy number states or total coverage ratio thresholds. In some embodiments, the called copy number alterations for one or more loci or one or more genomic segments are used to diagnose or confirm a diagnosis of a disease in a subject.
[0023] In any of the above methods, the method further comprises generating a genomic profile for the subject, the genomic profile comprising the called copy number changes for one or more loci or one or more genomic segments. In some embodiments, the subject's genomic profile further comprises results from a comprehensive genomic profiling test, a gene expression profiling test, a cancer hotspot panel test, a DNA methylation test, a DNA fragmentation test, an RNA fragmentation test, or any combination thereof. In some embodiments, the subject's genomic profile further comprises results from a nucleic acid sequencing-based test. In any of the above methods, the method further comprises selecting an anti-cancer drug, administering an anti-cancer drug, or administering an anti-cancer treatment to the subject based on the generated genomic profile.
[0024] In an embodiment of any of the above methods, the method comprises using the called copy number alterations for one or more genetic loci or one or more genomic segments in making suggested treatment decisions for the subject.
[0025] In an embodiment of any of the above methods, the method further includes using the called copy number changes for one or more genetic loci or one or more genomic segments in administering or administering a treatment to a subject.
[0026] Also described herein are methods for diagnosing a disease, the method comprising determining that a subject has the disease based on called copy number changes for one or more genetic loci or one or more genomic segments, wherein the called copy number changes for the one or more genetic loci or one or more genomic segments are determined according to any one of the methods described above.
[0027] Also described herein is a method for identifying a subject as eligible for a clinical trial for the treatment of a disease, comprising determining that the subject has the disease based on the called copy number changes for one or more loci or one or more genome segments, wherein the called copy number changes for one or more loci or one or more genome segments are determined according to any one of the above methods. In some embodiments, the method further comprises enrolling the subject in the clinical trial. In some embodiments, the method further comprises administering a treatment to the subject. In some embodiments, the treatment is an anti-cancer treatment.
[0028] In some embodiments, the disease is cancer. In some embodiments, the disease is a genetic disease, such as a disease associated with chromosomal aneuploidy (e.g., Down's syndrome, Edwards syndrome, or Patau syndrome) or fragile X. In some embodiments, the disease is cancer, and the method further comprises selecting an anti-cancer therapy for administration to the subject based on the called copy number changes for one or more genetic loci or one or more genomic segments.
[0029] Also described herein is a method of selecting an anti-cancer therapy for a subject having cancer, the method comprising selecting an anti-cancer therapy for the subject in response to copy number changes for one or more genetic loci or one or more genome segments called according to the above method. In some embodiments, the method further comprises determining an effective amount of an anti-cancer therapy to administer to the subject based on the called copy number changes for one or more genetic loci or one or more genome segments. In some embodiments, the method further comprises administering an anti-cancer therapy to the subject based on the called copy number changes for one or more genetic loci or one or more genome segments.
[0030] Also described herein are methods of treating cancer in a subject, comprising administering to the subject an effective amount of an anti-cancer therapy in response to called copy number changes for one or more genetic loci or one or more genomic segments called according to the methods described above.
[0031] Also described herein is a method for monitoring tumor progression or recurrence in a subject, the method comprising: calling copy number changes for one or more genetic loci or one or more genome segments using a first sample obtained from the subject at a first time point according to the above method; calling copy number changes for one or more genetic loci or one or more genome segments using a second sample obtained from the subject at a second time point; and comparing the first called copy number changes for the one or more genetic loci or one or more genome segments to the second called copy number changes, thereby monitoring tumor progression or recurrence. In some embodiments, the called copy number changes for the one or more genetic loci or one or more genome segments using the second sample are determined according to the above method. In some embodiments, the method further comprises adjusting an anti-cancer treatment in response to tumor progression. In some embodiments, the method further comprises adjusting a dosage of the anti-cancer treatment or selecting a different anti-cancer treatment in response to tumor progression. In some embodiments, the method further comprises administering the adjusted anti-cancer treatment to the subject. In some embodiments, the first time point is before the subject is administered the anti-cancer treatment and the second time point is after the subject is administered the anti-cancer treatment.
[0032] In some embodiments of the above methods, the subject has cancer, is at risk of having cancer, is routinely tested for cancer, or is suspected of having cancer.
[0033] In some embodiments of the above methods, the anti-cancer therapy or anti-cancer treatment comprises chemotherapy, radiation therapy, immunotherapy, targeted therapy, or surgery.
[0034] In some embodiments of the above methods, the cancer or tumor is a solid cancer. In some embodiments of the above methods, the cancer or tumor is a hematological cancer. In some embodiments of the above methods, the cancer or tumor is a B-cell cancer (multiple myeloma), melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, Chondrosarcoma, Cancer of the blood tissue, Adenocarcinoma, Inflammatory myofibroblastoma, Gastrointestinal stromal tumor (GIST), Colon cancer, Multiple myeloma (MM), Myelodysplastic syndrome (MDS), Myeloproliferative disorder (MPD), Acute lymphocytic leukemia (ALL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), Chronic lymphocytic leukemia (CLL), Polycythemia Vera, Hodgkin's lymphoma, Non-Hodgkin's lymphoma (NHL), Soft tissue sarcoma, Fibrosarcoma, Myxoma Liquid sarcoma, liposarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, liver cancer, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, head Oticopharyngioma, ependymoma, pineal cell tumor, glioblastoma, acoustic neuroblastoma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, essential thrombocythemia, aplastic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familial eosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, or carcinoid tumor.
[0035] In some embodiments of the above methods, the method further comprises generating, by the one or more processors, a report indicating the copy number status or the called copy number changes for the one or more genomic loci or one or more genomic segments. In some embodiments of the above methods, the method further comprises transmitting the report to the subject or to a health care provider. In some embodiments, the report is transmitted over a computer network or a peer-to-peer connection.
[0036] In some embodiments of the above methods, the subject is suspected of having or determined to have cancer.
[0037] In some embodiments of the above methods, the methods further comprise obtaining a tissue sample from the subject.
[0038] In some embodiments of the above methods, the sample comprises a tissue biopsy sample, a liquid biopsy sample, or a normal control.
[0039] In some embodiments of the above methods, the sample is a liquid biopsy sample and comprises blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva.
[0040] In some embodiments of the above methods, the sample is a liquid biopsy sample and comprises circulating tumor cells (CTCs).
[0041] In some embodiments of the above methods, the sample is a liquid biopsy sample and comprises cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof.
[0042] In some embodiments of the above method, the plurality of nucleic acid molecules comprises a mixture of tumor nucleic acid molecules and non-tumor nucleic acid molecules.In some embodiments, the tumor nucleic acid molecules are derived from the tumor part of a heterogeneous tissue biopsy sample, and the non-tumor nucleic acid molecules are derived from the normal part of the heterogeneous tissue biopsy sample.In some embodiments, the sample comprises a liquid biopsy sample, the tumor nucleic acid molecules are derived from the circulating tumor DNA (ctDNA) fraction of the liquid biopsy sample, and the non-tumor nucleic acid molecules are derived from the non-tumor cell-free DNA (cfDNA) fraction of the liquid biopsy sample.
[0043] 1. A system comprising: one or more processors; and a memory communicatively coupled to the one or more processors and configured to store instructions, the instructions, when executed by the one or more processors, causing the system to: receive, at the one or more processors, sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject; generate, using the one or more processors, minor allele coverage ratios and major allele coverage ratios for a plurality of loci; segment, using the one or more processors, a genome into a plurality of genomic segments; and generate, using the one or more processors, (i) major allele coverage ratios for loci among the plurality of loci. Also described herein is a system that generates copy number grid model input data including (i) a difference between the gene coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio; fits, using one or more processors, a plurality of copy number grid models including allowed copy number states to the copy number grid model input data; selects, using one or more processors, a copy number grid model from the plurality of copy number grid models; and assigns, using one or more processors, copy number states for at least a portion of a plurality of genomic segments based on the selected copy number grid model.
[0044] In some embodiments of the system, the genome is segmented based on minor allele coverage ratio, major allele coverage ratio, or total coverage ratio.
[0045] In some embodiments of the system, the instructions that cause the system to select the selected copy number grid model include instructions that cause the system to determine, for each genome segment, a distribution of copy number grid model input data; identify, for each genome segment, a distance between the distribution and a closest copy number state; and determine an overall model fit score based on an average distance across multiple genome segments.
[0046] In some embodiments of the system, different copy number grid models in the plurality of copy number grid models are initialized using different initial tumor purity estimates and tumor ploidy estimates.
[0047] In some embodiments of the system, the instructions for fitting the allowed copy number states to the transformed coverage ratio data include instructions that cause the system to fit the allowed copy number states to the copy number grid model input data based on an initial tumor purity estimate and an initial tumor ploidy estimate; iteratively assigning preliminary copy numbers to each segment of the plurality of segments; determining an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignments; and re-fitting the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate.
[0048] In some embodiments of the system, the initial tumor purity is constrained by a preselected lower tumor purity limit and a preselected upper tumor purity limit. In some embodiments, the preselected lower tumor purity limit is 0 and the preselected upper tumor purity limit is 1.
[0049] In some embodiments of the system, the initial tumor ploidy is constrained by a preselected tumor ploidy lower limit. In some embodiments, the preselected tumor ploidy lower limit is about 1.1 to about 1.5. In some embodiments of the system, the initial tumor ploidy is constrained by a preselected tumor ploidy upper limit. In some embodiments of the system, the preselected tumor ploidy lower limit is about 6 to about 10.
[0050] In some embodiments of the system, the assigned copy number state for each of the plurality of genome segments is a total copy number count for the genome segment, a minor allele copy number count for the genome segment, or a major allele copy number count for the genome segment.
[0051] In some embodiments of the system, the genome is segmented into a plurality of genome segments using a circular binary segmentation (CBS) method, a maximum likelihood method, a hidden Markov chain method, a walking Markov method, a Bayesian method, a long-range correlation method, or a change-point method. In some embodiments, the segmentation step is performed using a change-point method, and the change-point method is a pruned exact linear time (PELT) method.
[0052] In some embodiments of the system, the system further comprises an electronic display, and the instructions, when executed by the one or more processors, further cause the system to overlay the selected copy number grid model and the copy number grid model input data to generate an overlay, and display the overlay.
[0053] In some embodiments of the system, the system further includes instructions that, when executed by the one or more processors, cause the system to call copy number alterations for one or more loci or one or more genomic segments based on one or more assigned copy number states or total coverage ratio thresholds.
[0054] In some embodiments of the system, the system further comprises instructions that, when executed by the one or more processors, cause the system to generate a report indicating the copy number status or called copy number changes for one or more genomic loci or one or more genomic segments. In some embodiments, the system further comprises instructions that, when executed by the one or more processors, cause the system to transmit the report to a subject or a health care provider. In some embodiments, the report is transmitted over a computer network or a peer-to-peer connection.
[0055] A non-transitory computer readable storage medium storing one or more programs, the one or more programs including instructions that, when executed by one or more processors of the system, cause the system to: receive, with the one or more processors, sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject; generate, using the one or more processors, minor allele coverage ratios and major allele coverage ratios for the plurality of loci; segment, using the one or more processors, the genome into a plurality of genome segments; and generate, using the one or more processors, (i) major allele coverage ratios and major allele coverage ratios for loci among the plurality of loci. Also described herein is a non-transitory computer-readable storage medium that causes a computer to: generate copy number grid model input data including (i) a difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio; fit, using one or more processors, a plurality of copy number grid models including allowed copy number states to the copy number grid model input data; select, using the one or more processors, a selected copy number grid model from the plurality of copy number grid models; and assign, using the one or more processors, a copy number state for at least a portion of a plurality of genomic segments based on the selected copy number grid model.
[0056] In some embodiments of the non-transitory computer readable storage medium, the genome is segmented based on a minor allele coverage ratio, a major allele coverage ratio, or a total coverage ratio.
[0057] In some embodiments of the non-transitory computer readable storage medium, the instructions that cause the system to select the selected copy number grid model include instructions that cause the system to determine, for each genome segment, a distribution of copy number grid model input data; identify, for each genome segment, a distance between the distribution and a closest copy number state; and determine an overall model fit score based on an average distance across multiple genome segments.
[0058] In some embodiments of the non-transitory computer-readable storage medium, different copy number grid models in the plurality of copy number grid models are initialized using different initial tumor purity estimates and tumor ploidy estimates.
[0059] In some embodiments of the non-transitory computer-readable storage medium, the instructions to the system to fit allowed copy number states to the copy number grid model input data include instructions to cause the system to fit allowed copy number states to the copy number grid model input data based on an initial tumor purity estimate and an initial tumor ploidy estimate; iteratively assigning preliminary copy numbers to each segment of the plurality of segments; determining an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignments; and re-fitting the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate.
[0060] In some embodiments of the non-transitory computer-readable storage medium, the initial tumor purity is constrained by a preselected lower tumor purity limit and a preselected upper tumor purity limit. In some embodiments, the preselected lower tumor purity limit is 0 and the preselected upper tumor purity limit is 1.
[0061] In some embodiments of the non-transitory computer readable storage medium, the initial tumor ploidy is constrained by a preselected tumor ploidy lower limit. In some embodiments, the preselected tumor ploidy lower limit is about 1.1 to about 1.5. In some embodiments, the initial tumor ploidy is constrained by a preselected tumor ploidy upper limit. In some embodiments, the preselected tumor ploidy lower limit is about 6 to about 10.
[0062] In some embodiments of the non-transitory computer readable storage medium, the assigned copy number state is a total copy number count for the genome segment, a minor allele copy number count for the genome segment, or a major allele copy number count for the genome segment.
[0063] In some embodiments of the non-transitory computer readable storage medium, the genome is segmented into a plurality of genome segments using a circular binary segmentation (CBS) method, a maximum likelihood method, a hidden Markov chain method, a walking Markov method, a Bayesian method, a long-range correlation method, or a change-point method. In some embodiments, the segmentation step is performed using a change-point method, and the change-point method is a pruned exact linear time (PELT) method.
[0064] In some embodiments of the non-transitory computer-readable storage medium, the system further comprises an electronic display, and the instructions, when executed by the one or more processors, further cause the system to overlay the selected copy number grid model and the copy number grid model input data to generate an overlay, and display the overlay.
[0065] In some embodiments of the non-transitory computer-readable storage medium, the storage medium further comprises instructions that, when executed by the one or more processors, cause the system to call copy number alterations for one or more loci or one or more genomic segments based on one or more assigned copy number states or total coverage ratio thresholds.
[0066] In some embodiments of the non-transitory computer readable storage medium, the storage medium further comprises instructions that, when executed by the one or more processors, cause the system to generate a report indicating the copy number status or called copy number changes for one or more genomic loci or one or more genomic segments. In some embodiments, the storage medium further comprises instructions that, when executed by the one or more processors, cause the system to transmit the report to a subject or a health care provider. In some embodiments, the report is transmitted over a computer network or a peer-to-peer connection. [Brief description of the drawings]
[0067] Various aspects of the disclosed methods, devices, and systems are set forth with particularity in the appended claims. A better understanding of the features and advantages of the disclosed methods, devices, and systems will be obtained by reference to the following detailed description of exemplary embodiments and the accompanying drawings.
[0068] [Figure 1] 1 provides a set of exemplary copy number grid points for a plot of the difference between major and minor allele coverage ratios versus the sum of major and minor allele coverage ratios. [Figure 2A] 1 shows an exemplary copy number grid in copy number space, where minor allele copy numbers and major allele copy numbers are plotted against each other. [Figure 2B] 2B shows the exemplary copy number grid of FIG. 2A scaled by assuming a purity of 0.95 and a ploidy of 2 in the illustrated example. [Figure 2C]
number
[0069] Described herein are methods and systems for calling copy number alterations (CNAs), including methods and systems for fitting a grid-based copy number model (i.e., a "copy number grid model") to sequence read data. For example, copy number alterations for a subject's tumor can be called. A sample from a subject can include, for example, a mixture of tumor and non-tumor nucleic acid molecules. While copy number states for healthy (e.g., non-tumor) tissues include euploid subjects with a single maternal allele and a single paternal allele, copy number alteration events in tumors make calling the copy number state of a tumor more difficult, especially when the tumor ploidy and / or tumor purity of the sample are a priori unknown. The methods described herein allow for calling the copy number state of genomic segments in the genome of a diseased tissue (e.g., tumor).
[0070] The methods described herein may use sequence read data to generate minor and major allele coverage ratios for each of a plurality of loci. The genome may be segmented into a plurality of genome segments based on, for example, the minor allele coverage ratio, the major allele coverage ratio, or the total coverage ratio. The minor and major allele coverage ratios may be transformed to generate copy number grid model input data, which may include (i) the difference between the major and minor allele coverage ratios, and (ii) the sum of the major and minor allele coverage ratios.
[0071] Since copy number change events are necessarily integer events, plotting the difference between allele coverage ratios against the sum of allele coverage ratios should provide evenly spaced grid points unless there is any noise in the system. In reality, sequence read data contains noise that generally prevents perfect matching between the transformed coverage ratio data (i.e., copy number grid model input data) and the grid points. By fitting multiple copy number grid models to the copy number grid model input data, a copy number grid model that can be used to identify copy number states for at least a portion of the genome segment can be selected (e.g., best-fit copy number grid model). The copy number grid model includes allowed copy number states. As further described herein, the copy number models in the multiple copy number grid models can be initialized using different combinations of initial tumor purity estimates and tumor ploidy estimates that do not need to be known a priori. The selected copy number grid model can be overlaid with the copy number grid model input data, and the overlay is displayed, for example, in an interface output on an electronic display or a printed report. This allows for easy viewing of the data and facilitates manual calling of copy number changes or confirmation of called copy number changes (eg, copy number changes called by an automated process).
[0072] The copy number state assigned using the model can be a total copy number count for a genome segment, a minor allele copy number count for a genome segment, or a major allele copy number count for a genome segment. The segmentation can be based on the approximation of equal copy numbers of genomic loci within the segment. Thus, genomic loci within a segment can be assumed to have the same copy number state as the genome segment itself. Copy number changes for one or more loci can be called based on the copy number state assigned to the corresponding genome segment (e.g., calling whether a copy number change has occurred, calling a copy number gain, calling a copy number gain, or calling a number of calls).
[0073] definition Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0074] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Any reference to "or" herein is intended to include "and / or" unless specifically stated otherwise.
[0075] As used herein, the terms "comprising" (and any form or variation of comprising, such as "comprise" and "comprises"), "having" (and any form or variation of having, such as "have" and "has"), "including" (and any form or variation of including "includes" and "include"), or "containing" (and any form or variation of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unlisted additives, components, integers, elements, or method steps.
[0076] As used herein, the term "about" a number or value refers to that number or value plus or minus 10% of that number or value. When used in the context of a range, the term "about" refers to minus 10% of the lowest value and plus 10% of the highest value of that range.
[0077] As used herein, the term "subgenomic interval" (or "subgenomic sequence interval") refers to a portion of a genome sequence.
[0078] As used herein, the term "interval of interest" refers to a subgenomic interval or an expressed subgenomic interval (eg, a transcribed sequence of a subgenomic interval).
[0079] As used herein, the terms "mutant sequence" or "mutant" are used interchangeably and refer to a nucleic acid sequence that is modified relative to the corresponding "normal" or "wild-type" sequence. In some instances, the mutant sequence may be a "short mutant sequence" (or "short mutant"), i.e., a mutant sequence that is less than about 50 base pairs in length.
[0080] The terms "allele frequency" and "allele fraction" are used interchangeably herein and refer to the fraction of sequence reads that correspond to a particular allele relative to the total number of sequence reads for a genomic locus.
[0081] The terms "mutant allele frequency" and "mutant allele fraction" are used interchangeably herein and refer to the fraction of sequence reads that correspond to a particular mutant allele relative to the total number of sequence reads for a genomic locus.
[0082] As used herein, the term "segmentation" (or "sequence segmentation") refers to a process for dividing sequence read data into several non-overlapping segments that cover all sequence read data points, such that each segment of the plurality of segments is as homogeneous as possible and all sequence reads associated with a given segment have the same copy number. In some examples, segmentation can be performed by processing the aligned sequence read data (or other sequencing-related data derived from the sequence read data, such as coverage data, allele frequency data, etc.) using any of a variety of methods known to those skilled in the art (see, for example, Braun and Miller (1998), "Statistical methods for DNA sequence segmentation", Statistical Science 13(2):142-162). Examples of segmentation methods include, but are not limited to, circular binary segmentation (CBS), maximum likelihood, hidden Markov chain, walking Markov, Bayesian, long-range correlation, change-point, or any combination thereof.
[0083] As used herein, the term "ploidy" refers to the average copy number for multiple loci in tumor samples.In some instances, the "ploidy" of tumor samples may differ from the number of complete chromosome sets in cells, and thus the number of possible alleles for autosomal genes (i.e., genes located on numbered non-sex chromosomes), due to the heterogeneity of tumor samples (i.e., variations in tumor sample purity).
[0084] It will be understood that the embodiments and variations of the invention described herein include "consisting of" and / or "consisting essentially of" embodiments and variations.
[0085] When a range of values is provided, it is understood that each intervening value between the upper and lower limits of that range, and any other stated or intervening value within that stated range, is included within the scope of the disclosure. When a stated range includes an upper or lower limit, ranges excluding any of those included limits are also included in the disclosure.
[0086] Some of the analytical methods described herein include mapping a sequence to a reference sequence, determining sequence information, and / or analyzing sequence information. It is well understood in the art that complementary sequences can be readily determined and / or analyzed, and the descriptions provided herein encompass analytical methods performed with respect to complementary sequences.
[0087] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. The description is presented to enable one of ordinary skill in the art to make and use the invention and is provided in the context of a patent application and its requirements. Various modifications to the described embodiments will be readily apparent to those skilled in the art, and the generic principles of the present specification may be applied to other embodiments. Thus, the present invention is not intended to be limited to the embodiments shown, but is to be accorded the widest scope consistent with the principles and features described herein.
[0088] The figures illustrate processes according to various embodiments. In the example processes, some blocks are arbitrarily combined, the order of some blocks is arbitrarily changed, and some blocks are arbitrarily omitted. In some instances, additional steps may be performed in combination with the example processes. Thus, the operations illustrated (and described in more detail below) are exemplary in nature and therefore should not be considered limiting.
[0089] The disclosures of all publications, patents, and patent applications referenced herein are each incorporated herein by reference in their entirety. To the extent that a reference incorporated by reference conflicts with the present disclosure, the present disclosure shall control.
[0090] Methods for determining copy number The method described herein provides for the determination of copy number states of one or more genome segments of a genome from a sample of a subject. Sequencing read data associated with a plurality of nucleic acid molecules obtained from a sample from a subject can be used to generate a minor allele coverage ratio and a major allele coverage ratio for each of a plurality of loci. The genome of the subject can be segmented into a plurality of genome segments based on, for example, the minor allele coverage ratio, the major allele coverage ratio, or the total coverage ratio. The minor allele coverage ratio and the major allele coverage ratio for each of the loci can be converted to generate copy number grid model input data, which can include (i) the difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) the sum of the major allele coverage ratio and the minor allele coverage ratio. A plurality of copy number grid models including allowed copy number states can be fitted to the copy number grid model input data. Different copy number grid models in the plurality of copy number grid models can be initialized using different initial tumor purity estimates and tumor ploidy estimates. A copy number grid model can be selected from a plurality of copy number grid models. Copy number states for at least a portion of the plurality of genome segments can then be assigned based on the selected copy number grid model.
[0091] Major and minor allele frequencies (e.g., SNP allele frequencies) and total coverage ratios (i.e., the sum of major and minor allele coverages normalized by a normalization factor) can be determined from the sequence read data. Coverage ratio data for a sample (e.g., a patient tumor sample) can be determined, for example, by aligning multiple sequence reads that overlap one or more loci within one or more subgenomic intervals in the sample and in the control (e.g., a pair of normal controls, process matched controls, or "panel of normal" controls) to a reference genome (e.g., the GRCh38 human reference genome) and determining the number of sequence reads that overlap each of one or more loci within one or more subgenomic intervals in the sample and in the control to normalize the coverage for the tumor sample to the coverage in the control. In some examples, for example, when a pair of normal control samples is not available, a process matched control (e.g., a mixture of DNA from multiple HapMap cell lines) can be used in place of a pair of normal controls to normalize the coverage. In some instances, for example, when a pair of normal control samples is not available, a "panel of normals" control can be used in place of a pair of normal controls to normalize coverage.
[0092] In some instances, a "panel of normal" or "tangent normalization" control method may be used to normalize sequencing coverage (see, for example, Tabak, et al. (2019) "The Tangent copy-number inference pipeline for cancer genome analyses", https: / / www.biorxiv.org / content / 10.1101 / 566505v1.full.pdf). Tangent normalization is a method of normalizing tumor data to address noise in the data. Specifically, tangent methods address reducing systemic noise that results from differences in the experimental conditions under which sequencing data from tumors and / or their normal controls were generated. It has been shown that tangent normalization methods result in greater reduction of noise than traditional normalization methods.
[0093] In the exemplary tangent normalization method, n N Let n be the number of normal samples. T Let i be the set {1,2,…,n N}, j is the set {1,2,…,n T} element of N i Define T as the vector of log2 copy ratio intensities at the genomic rank of the i-th normal sample. Similarly, T j Define j as the vector of log2 copy ratio intensities at the genomic rank of the jth tumor sample. The normal and tumor sample vectors are elements of an M-dimensional vector space of all possible coverage profiles. Here, we define the reference subspace N of the vector space of all possible coverage profiles as all linear combinations of the normal sample vectors {N1,N2,…,N nN}. N is called the "noise space" and (n N -1) It is a dimensional plane.
[0094] Given this setting, the tangent normalization method proceeds as follows: for each tumor sample vector T j For each T in noise space N, use the Euclidean metric j We start by determining the vector that is closest to p(T j ) and T j is the projection of p(T j ) is T j represents the profile of a normal sample characterized under similar conditions as j The normalization of T j and T j Projection of p(T j ) can be calculated by calculating the difference between: T j Normalization of = T j -p(T j ) Projection p(T j ) can be calculated directly using standard linear algebra techniques.
[0095] In some examples, allele fraction data for a sample (e.g., a patient tumor sample) is determined by aligning multiple sequence reads that overlap one or more loci within one or more subgenomic intervals in the sample to a reference genome (e.g., the GRCh38 human reference genome), detecting the number of different alleles present at one or more loci within one or more subgenomic intervals in the sample, and determining the allele fraction for the different alleles present at one or more loci by dividing the number of sequence reads identified for a given allele sequence by the total number of sequence reads identified for the locus.
[0096] Given the major and minor allele fractions and the coverage ratios for a given locus, a haploid coverage ratio (i.e., minor allele coverage ratio and major allele coverage ratio) can be generated from the sequence read data. The minor allele coverage ratio is proportional to the minor allele frequency and the total coverage ratio. Similarly, the major allele coverage ratio is proportional to the major allele frequency and the total coverage ratio. A scaling factor can be used to scale the minor and major allele coverage ratios to the total coverage ratio, for example, by multiplying the product of the total coverage ratio and the allele frequency by 2. For example, the major allele coverage ratio (R A ) and minor allele coverage ratio (R B ) can be determined as follows: R A =2*R*F A and R B =2*R*F B , where R is the total coverage ratio and F A and F B are the major and minor allele fractions, respectively.
[0097] The genome for a sample (e.g., a patient tumor sample) can be segmented into genome segments. Loci are thus binned within genome segments. The genome can be segmented, for example, by aligning multiple sequence reads that overlap one or more loci in one or more subgenomic intervals in the sample to a reference genome (e.g., the GRCh38 human reference genome) and processing the aligned sequence read data (or other sequencing-related data derived from the sequence read data, such as total coverage ratio data, allele frequency data, etc.) using a segmentation algorithm (e.g., circular binary segmentation (CBS) method, maximum likelihood method, hidden Markov chain method, walking Markov method, Bayesian method, long-range correlation method, change-point method, or any combination thereof) to generate multiple non-overlapping segments such that sequences associated with a given segment have the same copy number. In some examples, segmented data for a sample (e.g., a patient tumor sample) can be generated using a pruning exact linear time (PELT) method to determine the number of segments required to properly take into account the aligned sequence read data (or other sequencing-related data derived from the sequence read data, e.g., coverage ratio data, allele frequency data, etc.), such that each segment (and the sequence reads associated with a segment) has the same copy number.
[0098] The allele coverage ratio for a locus is a function of the allele copy number, the tumor purity of the sample (i.e., the proportion of nucleic acid molecules in the sample that are of tumor origin versus non-tumor origin), and the tumor ploidy.
number
[0099] The data minor allele coverage ratio and major allele coverage ratio can be transformed to generate transformed coverage ratio data (i.e., copy number grid model input data) so that a copy number grid model can be fitted to the data. The transformed coverage ratio data is calculated by: (i) calculating the difference between the major allele coverage ratio and the minor allele coverage ratio (i.e., R A -R B ), and (i) the sum of the major and minor allele coverage ratios (i.e., R A +R B The difference between the major and minor allele coverage ratios is related to copy number, tumor purity, and ploidy as follows:
number
number
number
number
[0100] The copy number grid model represents a copy number space scaled and transformed as a function of ploidy and tumor purity values. FIG. 2A shows an exemplary copy number grid in copy number space, where minor allele copy numbers and major allele copy numbers are plotted against each other. Copy numbers are necessarily integer values, so the plot provides an evenly spaced grid. That is, the copy number grid model can include allowed copy number states (i.e., integer values for each of the major and minor allele copy numbers) as represented by grid points. The copy number grid model parameters β0 (transformation parameter) and β1 (scaling parameter) can be defined as follows:
number
[0101] The scaled copy number grid model parameters can be used to scale the minor allele copy number and major allele copy number axes. The copy number axis can take into account additional factors, such as
number
number
number
number
[0102] By generating the copy number grid, a nonlinear parameter space (p, Ψ) has been transformed into a linear parameter space (β0, β1). Moreover, perhaps a more important aspect of this representation is the stability in calling significant copy number events with respect to degenerate solutions. The copy number grid coordinate system allows β1 to represent the distance between adjacent states or the density of states. Furthermore, the copy number grid can establish a "zero level" such that β0 will necessarily remain the same for copy number states with zero copies, no matter what copy number grid model is fitted to the transformed data. The advantage of this transformation is twofold. First, all solutions will contain the same zero level solution, while there are still two parameters to search. There is still degeneracy between the separation of copy number events, but the starting point of the grid does not change, only the separation between grid points changes. By constraining one of the inference parameters to a fixed minimum ratio, the search has been simplified to the separation between states. Furthermore, the system provides a method of calling for significant copy number events, where significance can be defined by the zero level (a fixed parameter) regardless of the separation. Under this methodology, it is no longer necessary to know the copy number precisely in order to make copy number variation calls.
[0103] Ploidy and tumor purity values for a sample are unknown a priori. Therefore, multiple copy number grid models can be initialized using different initial tumor purity and tumor ploidy estimates.
[0104] In some embodiments, the initial tumor purity estimate is bounded by a preselected initial tumor purity estimate lower limit and / or exceeds a preselected initial tumor purity estimate upper limit. In some embodiments, the preselected initial tumor purity estimate lower limit is 0, 0.001, 0.005, 0.01, or any value between these ranges. In some embodiments, the preselected initial tumor purity estimate lower limit is 0. In some embodiments, the preselected initial tumor purity estimate upper limit is 1, 0.999, 0.995, 0.99, or any value between these ranges. In some embodiments, the preselected initial tumor purity estimate upper limit is 1.
[0105] In some embodiments, the initial tumor ploidy estimate is bounded by a preselected lower limit of the initial tumor ploidy estimate and / or exceeds a preselected upper limit of the initial tumor ploidy estimate. In some embodiments, the preselected lower limit of the initial tumor ploidy estimate is set at about 1.1 to about 1.5, e.g., 1.2. In some embodiments, the lower limit of the initial tumor ploidy estimate is 1.2. In some embodiments, the preselected upper limit of the initial tumor ploidy estimate is about 6 to about 10. In some embodiments, the preselected upper limit of the initial tumor ploidy estimate is 8.
[0106] In some embodiments, the initial tumor purity estimate and / or tumor ploidy are constrained by physical space (e.g., physical tumor purity can never go below 0 or above 1, with preselected tumor purity estimate lower and upper limits set to 0 and 1 or 0-1), but the initial or modeled tumor purity estimate and / or tumor ploidy estimate need not be limited to physical space. Due to model degeneracy, there may be copy number models that are solvable in non-physical space (e.g., purity > 1.0). These solutions are non-physical, but one may fit the model in non-physical space and use the relationship between the degenerate solutions to find physical values. That is, the non-physical purity may be converted back to physical purity or physical ploidy. In some embodiments, the initial tumor purity and / or initial tumor ploidy for multiple copy number grid models may include non-physical tumor purity estimates and / or non-physical tumor ploidy. In some embodiments, the initial tumor purity and / or initial tumor ploidy for multiple copy number grid models can include an imaginary tumor purity estimate and / or an imaginary tumor ploidy estimate.
[0107] A different copy number grid model can then be fitted to the transformed coverage ratio data. As an example, for any given copy number grid model, the allowed copy number states of the copy number grid model can be fitted to the transformed coverage ratio data based on the initial tumor purity estimate and the initial tumor ploidy estimate. A preliminary copy number can be assigned to each genome segment of the multiple genome segments. The loci within the genome segment are assumed to have the same copy number, but the transformed coverage ratio data of the loci within the genome segment form a 2D Gaussian distribution. The assignment can be based, for example, on the closest allowed copy number state for the genome segment. For example, a distance, such as a Mahalanobis distance, from the allowed copy number state can be determined for the gene segment based on the location of the transformed coverage ratio data of the loci within the genome segment. Once the preliminary copy number assignment is made to the genome segment, the loci within the genome segment, the updated tumor ploidy estimate and the updated tumor purity estimate can be determined accordingly. The allowed copy number states can then be refitted to the transformed coverage ratio data based on the updated tumor ploidy estimate and the updated tumor purity estimate. However, once the updated tumor purity estimate and the tumor ploidy estimate are determined, the optimal copy number state assignment may no longer be optimal. Thus, the process of assigning a preliminary copy number to each genome segment of the plurality of genome segments, determining an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignment, and refitting the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate can be performed iteratively until convergence (i.e., local fit maximum).
[0108] After fitting the multiple copy number grid models, a copy number grid model can be selected from the multiple. As discussed above, the transformed coverage ratio data of the loci in the genome segment forms a 2D Gaussian distribution that can be determined. In some embodiments of the method, a distance, such as the Mahalanobis distance, for each genome segment from the assigned copy number state can be assigned. An overall model fit score can be determined based on the average distance between the multiple genome segments and the corresponding assigned copy number state. The models can be ranked based on the overall model fit score, but the model selected does not have to be the model with the highest overall model fit score. For example, one or more filters can be applied to the models to filter out certain models. That is, a single best fit may not indicate the best model. For example, the models can be filtered by one or more of (i) a preselected ploidy range, (ii) a preselected purity range, (iii) a difference between a noise parameter and a copy number state with an interval in the model, (iv) a model with a ploidy above a preselected value when a corresponding low ploidy model is viable, or other desired filtering parameters.
[0109] In some embodiments, a model may be excluded if the model has a tumor purity below a preselected tumor purity lower limit and / or above a preselected tumor purity upper limit. In some embodiments, the preselected tumor purity lower limit is 0, 0.001, 0.005, 0.01, or any value between these ranges. In some embodiments, the preselected tumor purity lower limit is 0. In some embodiments, the preselected tumor purity upper limit is 1, 0.999, 0.995, 0.99, or any value between these ranges. In some embodiments, the preselected tumor purity upper limit is 1.
[0110] In some embodiments, a model may be excluded if the model has a tumor ploidy below a preselected tumor ploidy lower limit and / or above a preselected tumor ploidy upper limit. In some embodiments, the preselected tumor ploidy lower limit is set to about 1.1 to about 1.5, e.g., 1.2. In some embodiments, the preselected tumor ploidy lower limit is 1.2. In some embodiments, the preselected tumor ploidy upper limit is about 6 to about 10. In some embodiments, the preselected tumor purity upper limit is 8.
[0111] The selected copy number grid model can then be used to assign copy number states to at least a portion or all of the genome segments. The assigned copy number state can be, for example, the total copy number count (i.e., the sum of the major and minor allele copy numbers), the minor allele copy number count, or the major allele copy number count for the tumor or cancer of interest. The assignment can be based on the closest allowed copy number state for the genome segment, for example, taking into account the distribution of transformed coverage ratio data for the loci corresponding to the genome segment. For example, a distance, such as a Mahalanobis distance, from an allowed copy number state can be determined for the gene segment based on the location of the transformed coverage ratio data for the loci within the genome segment.
[0112] A particular advantage of the method described herein is that a copy number grid model can be generated using the allele fraction and allele coverage data (e.g., using an interface output on an electronic display). Thus, a particular genomic segment or particular genomic locus can be selected for easy visualization of copy number status. An exemplary interface including a selected copy number grid model with transformed coverage ratio data is shown in FIG. 3.
[0113] In the interface shown in FIG. 3, the transformed coverage ratio data for multiple loci are presented as black dots on a plot. A copy number grid model 302 is presented along with the transformed coverage ratio data. In a noiseless system, the transformed coverage ratio data would be perfectly focused on grid points (grid line intersections) that represent integer copy number states. The grid line spacing and grid translocations depend on the determined purity and ploidy values, which in the presented example are 0.614 and 3.739, respectively. Points representing genome segments may also be included in the interface, which are optionally proportional to the distribution of transformed coverage ratio data for genome loci within the genome segment. This allows for easy visualization of how close a genome segment copy number state is from an allowed copy number state.
[0114] The copy number grid model also facilitates calling copy number changes for one or more genomic loci or one or more genomic segments and improves the quality of the raw material. In one embodiment, copy number changes can be called based on the assigned copy number state for one or more genomic loci or one or more genomic segments that are non-diploid. In one embodiment, copy number changes can be called based on the assigned copy number state for one or more genomic loci or one or more genomic segments that are above a predetermined copy number threshold. The predetermined copy number threshold can be selected based on a desired risk tolerance or for a particular gene. For example, a particular gene may have a higher predetermined copy number threshold than other genes. In some embodiments, a total coverage ratio (i.e., the sum of the major allele coverage ratio and the minor allele coverage ratio) threshold can be used to call copy number changes. An exemplary total coverage ratio 306 is shown in FIG. 3 and is set to 3.5. In FIG. 3, genomic segments 308 that are above the threshold 306 are circled with a dashed line and copy number changes can be called for these genomic segments.
[0115] FIG. 4 illustrates an exemplary method for determining copy number states for one or more loci or one or more genome segments. At 402, sequence read data for a plurality of sequence reads is received, e.g., at one or more processors of an electronic (e.g., computer) system. The sequence read data is associated with a plurality of nucleic acid molecules obtained from a sample from a subject. The sample may, for example, include a mixture of nucleic acid molecules from tumor tissue and non-tumor tissue, or may include cell-free DNA, including cell-free tumor DNA and cell-free non-tumor DNA. At 404, minor allele coverage ratios and major allele coverage ratios are generated for a plurality of loci, e.g., using one or more processors. At 406, a genome (e.g., a reference genome appropriate for the subject) is segmented, e.g., using one or more processors, to generate a plurality of genome segments. The segmentation may, for example, be based on minor allele coverage ratios, major allele coverage ratios, or total coverage ratios. Segmenting the genome may identify contiguous portions of the genome that are grouped together based on having similar coverage ratios and thus are presumed to have similar copy number states. Thus, loci within a genome segment may be assumed to have the same copy number state. At 408, the minor and major allele coverage ratios for the loci may be transformed, for example, using one or more processors, to generate copy number grid model input data. The copy number grid model input data may include (i) the difference between the major and minor allele coverage ratios, and (i) the sum of the major and minor allele coverage ratios. At 410, a plurality of copy number grid models are fitted to the copy number grid model input data. The copy number grid models may include allowed copy number states (e.g., integer states) and may be parameterized using a tumor purity estimate and a tumor ploidy estimate. Different copy number grid models in the multiple copy number grid models can be initialized using different initial tumor purity and tumor ploidy estimates.At 412, a copy number grid model may be selected from a plurality of copy number grid models. As discussed above, the selected copy number grid model may not necessarily be the copy number grid model with the most optimal fit, since one or more copy number grid model filters may be applied to remove unfavorable or impossible models. Nevertheless, the copy number grid model selection may be based at least in part on an overall model fit score. At 414, copy number states may be assigned to at least a portion of the genome segments based on the selected copy number grid model. Optionally, at 416, the selected copy number grid model may be overlaid with the copy number grid model input data, for example, via an electronic display interface. Also optionally, at 418, a report may be generated indicating the copy number states or called copy number changes for one or more genomic loci or one or more genomic segments. The report may be transmitted, for example, via a computer network or a peer-to-peer connection, to the subject, a health care provider, or some other third party.
[0116] In some examples, the disclosed methods include (i) obtaining a sample from a subject (e.g., a subject suspected of having or determined to have cancer); (ii) extracting nucleic acid molecules (e.g., a mixture of tumor and non-tumor nucleic acid molecules) from the sample; (iii) ligating one or more adapters (e.g., one or more amplification primers, flow cell adapter sequences, substrate adapter sequences, or sample index sequences) to the nucleic acid molecules extracted from the sample; (iv) amplifying the nucleic acid molecules (e.g., using a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique); and (v) hybridizing the nucleic acid molecules to one or more bait molecules, each of which comprises one or more nucleic acid molecules that each comprise a region complementary to a region of the captured nucleic acid molecule (e.g., a region complementary to a region of the captured nucleic acid molecule). (vi) capturing the nucleic acid molecules from the amplified nucleic acid molecules (by chromatographic amplification); (vi) sequencing the nucleic acid molecules extracted from the sample (or library proxies derived therefrom), e.g., using a next-generation (e.g., massively parallel) sequencer, e.g., using next-generation (massively parallel) sequencing technology, whole genome sequencing (WGS) technology, whole exome sequencing technology, targeted sequencing technology, direct sequencing technology, or Sanger sequencing technology; and (vii) generating, displaying, transmitting, and / or delivering a report (e.g., electronic report, web-based report, or paper report) to a subject (or patient), a caregiver, a health care provider, a physician, an oncologist, an electronic medical record system, a hospital, a clinic, a medical clinic, a third-party payer, an insurance company, or a government agency. In some examples, the report comprises an output from a method described herein. In some examples, all or a portion of the report may be displayed in a graphical user interface of an online or web-based health care portal. In some examples, the report is transmitted over a computer network or a peer-to-peer connection.
[0117] The disclosed methods can be used with any of a variety of samples. For example, in some examples, the sample can include a tissue biopsy sample, a liquid biopsy sample, or a normal control. In some examples, the sample can be a liquid biopsy sample and can include blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva. In some examples, the sample can be a liquid biopsy sample and can include circulating tumor cells (CTCs). In some examples, the sample can be a liquid biopsy sample and can include cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof.
[0118] In some examples, the nucleic acid molecule extracted from the sample may comprise a mixture of tumor nucleic acid molecule and non-tumor nucleic acid molecule.In some examples, the tumor nucleic acid molecule may be derived from the tumor part of the heterogeneous tissue biopsy sample, and the non-tumor nucleic acid molecule may be derived from the normal part of the heterogeneous tissue biopsy sample.In some examples, the sample may comprise a liquid biopsy sample, and the tumor nucleic acid molecule may be derived from the circulating tumor DNA (ctDNA) fraction of the liquid biopsy sample, while the non-tumor nucleic acid molecule may be derived from the non-tumor cell-free DNA (cfDNA) fraction of the liquid biopsy sample.
[0119] In some examples, the disclosed methods can be used to diagnose the presence of a disease (e.g., cancer) in a subject (e.g., a patient). In some examples, the disclosed methods can be applicable to the diagnosis of any of a variety of cancers, as described elsewhere herein. In some embodiments, the disease is a genetic disease, such as a disease associated with a chromosomal aneuploidy (e.g., Down's syndrome, Edwards' syndrome, or Patau's syndrome) or fragile X.
[0120] In some examples, the disclosed methods can be used to identify subjects eligible for a clinical trial for the treatment of a disease. The method can further include enrolling the subject in the clinical trial and / or administering a treatment to the subject. In some examples, the disease can be cancer. In some examples, the disease is a disease associated with a chromosomal aneuploidy (e.g., Down's syndrome, Edwards syndrome, or Patau syndrome) or fragile X.
[0121] In some examples, the disclosed methods can be used to select an appropriate therapy or treatment (e.g., a cancer therapy or treatment) for a subject. In some examples, for example, the cancer therapy or treatment can include the use of a poly(ADP-ribose) polymerase inhibitor (PARPi), a platinum compound, chemotherapy, radiation therapy, targeted therapy (e.g., immunotherapy), surgery, or any combination thereof.
[0122] In some examples, the disclosed methods can be used in treating a disease (e.g., cancer) in a subject. For example, in response to determining that CNA occurs at one or more loci in a patient sample using any of the methods disclosed herein, an effective amount of a cancer therapy or treatment can be administered to the subject.
[0123] In some examples, the disclosed methods can be used to monitor disease progression or recurrence in a subject (e.g., cancer or tumor progression or recurrence). For example, in some examples, the methods can be used to detect CNAs in a first sample obtained from a subject at a first time point and to detect CNAs in a second sample obtained from the patient at a second time point, and a comparison of the first determination of CNAs and the second determination of CNAs allows for monitoring disease progression or recurrence. In some examples, the first time point is selected before the patient is administered the therapy or treatment, and the second time point is selected after the subject is administered the therapy or treatment.
[0124] In some examples, the disclosed methods can be used to select subjects for clinical trials. For example, patients can be selected based on having copy number alterations in one or more genes that are called using the methods described herein.
[0125] In some examples, the disclosed methods can be used to adjust a therapy or treatment (e.g., a cancer treatment or cancer therapy) for a subject, for example, by adjusting a treatment dose and / or selecting a different treatment in response to a change in a called copy number alteration (CNA).
[0126] In some examples, the called CNAs determined using the disclosed methods can be used as a prognostic or diagnostic indicator associated with a sample. For example, in some examples, a prognostic or diagnostic indicator can include an indication of the presence of a disease (e.g., cancer) in a sample, an indication of the likelihood that a disease (e.g., cancer) is present in a sample, an indication of the likelihood (i.e., risk factor) that a subject from whom the sample was derived will develop a disease (e.g., cancer), or an indication of the likelihood that a subject from whom the sample was derived will respond to a particular therapy or treatment.
[0127] In some examples, the disclosed methods can be implemented as part of a genomic profiling process that includes identifying the presence of variant sequences at one or more loci in a sample from a subject as part of detecting, monitoring, predicting risk factors, or selecting a treatment for a particular disease, e.g., cancer. In some examples, the variant panel selected for genomic profiling can include detection of variant sequences at a selected set of loci. In some examples, the variant panel selected for genomic profiling can include detection of variant sequences at several loci via comprehensive genomic profiling (CGP), a next-generation sequencing (NGS) approach used to evaluate hundreds of genes (including associated cancer biomarkers) in a single assay. Inclusion of the disclosed methods as part of a genomic profiling process (or inclusion of output from the disclosed methods for CNAs called as part of a subject's genomic profile) can improve the validity of, e.g., disease detection calls and treatment decisions made based on the genomic profile, e.g., by independently confirming the presence of CNAs at one or more loci in a given patient sample.
[0128] In some examples, a genomic profile may include information about the presence of genes (or variant sequences thereof), copy number variations, epigenetic traits, proteins (or modifications thereof), and / or other biomarkers in an individual's genome and / or proteome, as well as the individual's corresponding phenotypic traits, and information about the interactions between genetic or genomic traits, phenotypic traits, and environmental factors.
[0129] In some examples, the subject's genomic profile may include results from a comprehensive genomic profiling (CGP) test, a nucleic acid sequencing-based test, a gene expression profiling test, a cancer hotspot panel test, a DNA methylation test, a DNA fragmentation test, an RNA fragmentation test, or any combination thereof.
[0130] In some examples, the method may further include administering or applying a treatment or therapy (e.g., an anti-cancer agent, anti-cancer treatment, or anti-cancer therapy) to the subject based on the generated genomic profile. An anti-cancer agent or anti-cancer treatment may refer to a compound that is effective in treating cancer cells. Examples of anti-cancer agents or anti-cancer treatments include, but are not limited to, alkylating agents, antimetabolites, natural products, hormones, chemotherapy, radiation therapy, immunotherapy, surgery, or treatments configured to target defects in a particular cell signaling pathway, such as defects in the DNA mismatch repair (MMR) pathway.
[0131] sample The disclosed methods and systems may be used with any of a variety of samples (also referred to herein as specimens) containing nucleic acids (e.g., DNA or RNA) collected from a subject (e.g., a patient). Examples include, but are not limited to, a tumor sample, a tissue sample, a biopsy sample, a blood sample (e.g., a peripheral whole blood sample), a plasma sample, a serum sample, a lymph sample, a saliva sample, a sputum sample, a urine sample, a gynecological fluid sample, a circulating tumor cell (CTC) sample, a cerebrospinal fluid (CSF) sample, a pericardial fluid sample, a pleural fluid sample, an ascites (peritoneal fluid) sample, a feces (or stool) sample, or other bodily fluid, secretion, and / or excretion sample (or a cell sample derived therefrom). In certain examples, the sample may be a frozen sample or a formalin-fixed paraffin-embedded (FFPE) sample.
[0132] In some examples, samples may be collected by tissue resection (e.g., surgical resection), needle biopsy, bone marrow biopsy, bone marrow aspirate, skin biopsy, endoscopic biopsy, fine needle aspiration, oral swab, nasal swab, vaginal swab, or cytological smear, scraping, lavage or washing (such as luminal lavage or bronchoalveolar lavage), or the like.
[0133] In some examples, the sample is a liquid biopsy sample and may include, for example, whole blood, plasma, serum, urine, stool, sputum, saliva, or cerebrospinal fluid. In some examples, the sample is a liquid biopsy sample and may include circulating tumor cells (CTCs). In some examples, the sample is a liquid biopsy sample and may include cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof.
[0134] In some examples, the sample may include one or more pre-malignant or malignant cells. As used herein, a pre-malignant tumor refers to a cell or tissue that is not yet malignant, but is preparing to become malignant. In certain examples, the sample may be obtained from a solid tumor, a soft tissue tumor, or a metastatic lesion. In certain examples, the sample may be obtained from a hematological malignancy or a pre-malignancy. In other examples, the sample may include tissue or cells from a surgical margin. In certain examples, the sample may include tumor-infiltrating lymphocytes. In some examples, the sample may include one or more non-malignant cells. In some examples, the sample may be or be part of a primary tumor or metastasis (e.g., a metastasis biopsy sample). In some cases, the sample may be obtained from a site (e.g., a tumor site) with the highest percentage of tumor (e.g., tumor cells) compared to an adjacent site (e.g., a site adjacent to the tumor). In some cases, a sample may be obtained from a site (e.g., a tumor site) with the largest tumor lesion (e.g., the largest number of tumor cells as viewed under a microscope) compared to an adjacent site (e.g., a site adjacent to the tumor).
[0135] In some examples, the disclosed methods may further include analyzing a primary control (e.g., a normal tissue sample). In some examples, the disclosed methods may further include determining whether a primary control is available and, if so, isolating a control nucleic acid (e.g., DNA) from the primary control. In some examples, the sample may include an optional normal control (e.g., normal adjacent tissue (NAT)) if a primary control is not available. In some examples, the sample may be or include histologically normal tissue. In some examples, the method includes evaluating a sample, e.g., a histologically normal sample (e.g., from a surgical tissue margin), using the methods described herein. In some examples, the disclosed methods may further include obtaining a subsample enriched in non-tumor cells, e.g., by macro-dissecting non-tumor tissue from the NAT in a sample without a primary control. In some examples, the disclosed methods may further include determining that a primary control and NAT are unavailable and marking the sample for analysis without a matched control.
[0136] In some examples, samples obtained from histologically normal tissue (e.g., from otherwise histologically normal tissue margins) may still contain genetic alterations such as mutant sequences described herein. Thus, the method may further include reclassifying the sample based on the presence of the detected genetic alteration. In some examples, multiple samples (e.g., from different subjects) are processed simultaneously.
[0137] The disclosed methods and systems may be applied to the analysis of nucleic acids extracted from various tissue samples (or disease states thereof), such as any of solid tissue samples, soft tissue samples, metastatic lesions, or liquid biopsy samples. Examples of tissues include, but are not limited to, connective tissue, muscle tissue, nervous system tissue, epithelial tissue, and blood. Tissue samples may be collected from any organ within an animal or human body. Examples of human organs include, but are not limited to, the brain, heart, lung, liver, kidney, pancreas, spleen, thyroid, breast, uterus, prostate, large intestine, small intestine, bladder, bone, skin, etc.
[0138] In some examples, the nucleic acid extracted from the sample may include deoxyribonucleic acid (DNA) molecules. Examples of DNA that may be suitable for analysis by the disclosed methods include, but are not limited to, mitochondrial DNA or fragments thereof, cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA). Cell-free DNA (cfDNA) is composed of fragments of DNA released from normal and / or cancer cells during apoptosis and necrosis, circulating in the bloodstream and / or accumulating in other body fluids. Circulating tumor DNA (cfDNA) is composed of fragments of DNA released from cancer cells and tumors, circulating in the bloodstream and / or accumulating in other body fluids.
[0139] In some instances, DNA is extracted from nucleated cells from a sample. In some instances, a sample has low nucleated cellularity, for example, when the sample is composed primarily of red blood cells, diseased cells containing excess cytoplasm, or tissue with fibrosis. In some instances, a sample with low nucleated cellularity may require more, for example, a larger tissue volume, for DNA extraction.
[0140] In some examples, the nucleic acid extracted from the sample may include ribonucleic acid (RNA) molecules. Examples of RNA that may be suitable for analysis by the disclosed methods include, but are not limited to, total cellular RNA, total cellular RNA after depletion of specific abundance RNA sequences (e.g., ribosomal RNA), cell-free RNA (cfRNA), messenger RNA (mRNA) or fragments thereof, poly(A)-tailed mRNA fraction of total RNA, ribosomal RNA (rRNA) or fragments thereof, transfer RNA (tRNA) or fragments thereof, and mitochondrial RNA or fragments thereof. In some examples, RNA may be extracted from the sample and converted to complementary DNA, for example, using a reverse transcription reaction. In some examples, cDNA is produced by random primed cDNA synthesis. In other examples, cDNA synthesis is initiated at the poly(A) tail of mature mRNA by priming with an oligo(dT)-containing oligonucleotide. Methods for depletion, poly(A) enrichment, and cDNA synthesis are well known to those skilled in the art.
[0141] In some examples, the sample may contain tumor content, including, for example, tumor cells or tumor cell nuclei. In some examples, the sample may contain tumor content with at least 5-50%, 10-40%, 15-25%, or 20-30% tumor cell nuclei. In some examples, the sample may contain tumor content of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50% tumor cell nuclei. In some examples, the percentage of tumor nuclei is determined (e.g., calculated) by dividing the number of tumor cells in the sample by the total number of all cells in the sample that have nuclei. In some examples, for example, when the sample is a liver sample containing hepatocytes, a different tumor content calculation may be required due to the presence of hepatocytes with double or more than double nuclei, the presence of other DNA content, e.g., non-hepatocyte, somatic cell nuclei. In some examples, the sensitivity of detection of genetic alterations, e.g., mutant sequences, or the sensitivity of determination of, e.g., microsatellite instability, may depend on the tumor content of the sample. For example, a sample with a lower tumor content may result in a lower sensitivity of detection for a sample of a given size.
[0142] In some instances, as described above, the sample contains nucleic acid (e.g., DNA, RNA (or cDNA derived from RNA), or both), e.g., from a tumor or from normal tissue. In certain instances, the sample may further contain non-nucleic acid components, e.g., cells, proteins, carbohydrates, or lipids, e.g., from the tumor or normal tissue.
[0143] subject In some examples, the sample is obtained (e.g., collected) from a subject (e.g., a patient) having or suspected of having a condition or disease (e.g., a hyperproliferative disease or a catabolic cancer). In some examples, the hyperproliferative disease is cancer. In some examples, the cancer is a solid tumor or a metastatic form thereof. In some examples, the cancer is a blood cancer, e.g., leukemia or lymphoma.
[0144] In some examples, the subject has cancer or is at risk of having cancer. For example, in some examples, the subject has a genetic predisposition to cancer (e.g., having a genetic mutation that increases the baseline risk for developing cancer). In some examples, the subject has been exposed to an environmental perturbation (e.g., radiation or chemicals) that increases the risk of developing cancer. In some examples, the subject needs to be monitored for the development of cancer. In some examples, the subject needs to be monitored for progression or regression of cancer, for example, after being treated with a cancer therapy. In some examples, the subject needs to be monitored for recurrence of cancer. In some examples, the subject needs to be monitored for minimal residual disease (MRD). In some examples, the subject has been or is being treated for cancer. In some examples, the subject has not been treated with a cancer therapy (or cancer treatment).
[0145] In some examples, a subject (e.g., a patient) is being treated or has previously been treated with one or more targeted therapies. In some examples, for example, for a patient who has previously been treated with a targeted therapy, a post-targeted therapy sample (e.g., a specimen) is obtained (e.g., collected). In some examples, a post-targeted therapy sample is a sample obtained after completion of the targeted therapy.
[0146] In some instances, the patient has not been previously treated with a targeted therapy. In some instances, for example, for patients who have not been previously treated with a targeted therapy, the sample is obtained from a resection, e.g., the original resection, or a resection following a recurrence (e.g., following disease recurrence following treatment).
[0147] cancer In some examples, the sample is obtained from a subject with cancer. Exemplary cancers include, but are not limited to, B-cell cancer (e.g., multiple myeloma), melanoma, breast cancer, lung cancer (such as non-small cell lung cancer or NSCLC), bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, gastric cancer, ovarian cancer, bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, oral or pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, and the like. Cancer of the small intestine or adnexa, cancer of the salivary gland, thyroid cancer, adrenal adenocarcinoma, osteosarcoma, chondrosarcoma, cancer of the blood tissue, adenocarcinoma, inflammatory myofibroblastic tumor, gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndrome (MDS), myeloproliferative disorder (MPD), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, Hodgkin's lymphoma, Non-Hodgkin's lymphoma (NHL), soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder cancer, epithelial carcinoma, glioma, astrocytic These include medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, essential thrombocythemia, agnogenic myeloid metaplasia, hypereosinophilic syndrome, systemic mastocytosis, familial hypereosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, and carcinoma-like tumors.
[0148] In some examples, the cancer is a hematological malignancy (or pre-malignancy). As used herein, hematological malignancy refers to a tumor of hematopoietic or lymphatic tissue, e.g., a tumor affecting the blood, bone marrow, or lymph nodes. Exemplary hematological malignancies include leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), hairy cell leukemia, acute monocytic leukemia (AMoL), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), or large granular lymphocytic leukemia), lymphoma (e.g., AIDS-related lymphoma, cutaneous T-cell lymphoma, Hodgkin's lymphoma (e.g., classical Hodgkin's lymphoma or nodal lymphocytic predominant), and / or pulmonary leukemia (PCL). Hodgkin's lymphoma), mycosis fungoides, non-Hodgkin's lymphoma (e.g., B-cell non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma, small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma) or T-cell non-Hodgkin's lymphoma (mycosis fungoides, anaplastic large cell lymphoma, or precursor T-lymphoblastic lymphoma)), primary central nervous system.
[0149] Nucleic Acid Extraction and Processing DNA or RNA can be extracted from tissue samples, biopsies, blood samples, or other bodily fluid samples using any of a variety of techniques known to those of skill in the art (see, e.g., Example 1 of International Patent Application Publication No. WO2012 / 092426; Tan, et al. (2009), "DNA, RNA, and Protein Extraction: The Past and The Present", J. Biomed. Biotech. 2009:574398; the technical literature for the Maxwell® 16 LEV Blood DNA Kit (Promega Corporation, Madison, WI); and the Maxwell 16 Buccal Swab LEV DNA Purification Kit Technical Manual (Promega Literature #TM333, January 1, 2011, Promega Corporation, Madison, WI)). Protocols for RNA isolation are disclosed, for example, in the Maxwell® 16 Total RNA Purification Kit Technical Bulletin (Promega Literature #TB351, August 2009, Promega Corporation, Madison, WI).
[0150] A typical DNA extraction procedure includes, for example, (i) collection of a fluid, cell, or tissue sample from which DNA is to be extracted; (ii) if necessary, disruption of cell membranes to release DNA and other cytoplasmic components (i.e., cell lysis); (iii) treatment of the liquid or lysed sample with a concentrated salt solution to precipitate proteins, lipids, and RNA, followed by centrifugation to separate the precipitated proteins, lipids, and RNA; and (iv) purification of the DNA from the supernatant to remove detergents, proteins, salts, or other reagents used during the cell membrane lysis step.
[0151] Disruption of cell membranes can be performed using a variety of mechanical shearing (e.g., French press or fine needle) or ultrasonic disruption techniques. The cell lysis step often involves the use of detergents and surfactants to dissolve lipid, cell and nuclear membranes. In some instances, the lysis step may further include the use of proteases to break down proteins and / or RNases to digest RNA in the sample.
[0152] Examples of suitable techniques for DNA purification include, but are not limited to, (i) precipitation in ice-cold ethanol or isopropanol followed by centrifugation (which may be enhanced by increasing the ionic strength, e.g., by adding sodium acetate, to precipitate the DNA); (ii) phenol-chloroform extraction followed by centrifugation to separate the aqueous phase containing the nucleic acids from the organic phase containing the denatured proteins; and (iii) solid-phase chromatography, in which the nucleic acids are adsorbed to a solid phase (e.g., silica or other) depending on the pH and salt concentration of the buffer.
[0153] In some instances, cellular and histone proteins bound to DNA can be removed by adding proteases or by precipitating the proteins with sodium acetate or ammonium acetate, or through extraction with a phenol-chloroform mixture prior to the DNA precipitation step.
[0154] In some instances, DNA may be extracted using any of a variety of suitable commercially available DNA extraction and purification kits, including, but not limited to, the QIAamp (for isolating genomic DNA from human samples) and DNAeasy (for isolating genomic DNA from animal or plant samples) kits from Qiagen (Germantown, MD), or the Maxwell® and ReliaPrep™ series from Promega (Madison, WI).
[0155] As noted above, in some examples, the sample may include a formalin-fixed (or formaldehyde-fixed, or paraformaldehyde-fixed), paraffin-embedded (FFPE) tissue preparation. For example, an FFPE sample may be a tissue sample embedded in a matrix, such as an FFPE block. Methods for isolating nucleic acids (e.g., DNA) from formaldehyde-fixed or paraformaldehyde-fixed, paraffin-embedded (FFPE) tissues are described, for example, in Cronin, et al., (2004) Am J Pathol. 164(1):35-42; Masuda, et al., (1999) Nucleic Acids Res. 27(22):4436-4443; Specht, et al., (2001) Am J Pathol. 158(2):419-429; Ambion RecoverAll™ Total Nucleic Acid Isolation Protocol (Ambion, Cat. No. AM1975, September 2008); Maxwell® 16 FFPE Plus LEV DNA Purification Kit Technical Manual (Promega Literature #TM349, February 2011); EZNA® FFPE DNA Kit Handbook (OMEGA bio-tek, Norcross, GA, product numbers D3399-00, D3399-01, and D3399-02, June 2009), as well as the QIAamp® DNA FFPE Tissue Handbook (Qiagen, Cat. No. 37625, October 2007). For example, the RecoverAll™ Total Nucleic Acid Isolation Kit uses xylene at high temperature to solubilize paraffin-embedded samples and captures nucleic acids through glass fiber filters. The Maxwell® 16 FFPE Plus LEV DNA Purification Kit is used with the Maxwell® 16 Instrument to purify genomic DNA from 1 to 10 μm sections of FFPE tissue.DNA is purified using silica-clad paramagnetic particles (PMPs) and eluted in low elution volumes. The EZNA® FFPE DNA Kit uses spin columns and a buffer system for isolation of genomic DNA. The QIAamp® DNA FFPE Tissue Kit uses QIAamp® DNA Micro technology for purification of genomic and mitochondrial DNA.
[0156] In some examples, the disclosed methods may further include determining or obtaining a yield value of the nucleic acid extracted from the sample and comparing the determined value to a reference value. For example, if the determined or obtained value is less than the reference value, the nucleic acid may be amplified before proceeding with library construction. In some examples, the disclosed methods may further include determining or obtaining a value for the size (or average size) of the nucleic acid fragments in the sample and comparing the determined or obtained value to a reference value, for example, a size (or average size) of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 base pairs (bps). In some examples, one or more parameters described herein may be adjusted or selected in response to this determination.
[0157] After isolation, the nucleic acid is typically dissolved in a slightly alkaline buffer, such as Tris-EDTA (TE) buffer, or in ultrapure water. In some examples, the isolated nucleic acid (e.g., genomic DNA) can be fragmented or sheared by using any of a variety of techniques known to those skilled in the art. For example, genomic DNA can be fragmented by physical shearing, enzymatic cleavage, chemical cleavage, and other methods known to those skilled in the art. Methods for DNA shearing are described, for example, in Example 4 of International Patent Application Publication No. 2012 / 092426. In some examples, alternative methods of DNA shearing can be used to avoid the ligation step during library preparation.
[0158] Library preparation In some examples, the nucleic acids isolated from the sample can be used to construct a library (e.g., a nucleic acid library described herein). In some examples, the nucleic acids are fragmented using any of the methods described above, optionally subjected to repair of strand end damage, optionally ligated to synthesize adapters, primers, and / or barcodes (e.g., amplification primers, sequence adapters, flow cell adapters, substrate adapters, sample barcodes or indexes, and / or unique molecular identifier sequences), size selected (e.g., by preparative gel electrophoresis), and / or amplified (e.g., using PCR, non-PCR amplification techniques, or isothermal amplification techniques). In some examples, the fragmented and adapter-ligated nucleic acid population is used without explicit size selection or amplification prior to hybridization-based selection of target sequences. In some examples, the nucleic acids are amplified by any of a variety of specific or non-specific nucleic acid amplification methods well known to those of skill in the art. In some examples, the nucleic acids are amplified by whole genome amplification methods, such as, for example, random primed strand displacement amplification. Examples of nucleic acid library preparation techniques for next generation sequencing are described, for example, in van Dijk, et al. (2014), Exp. Cell Research 322:12-20, and Illumina's genomic DNA sample preparation kit.
[0159] In some examples, the resulting nucleic acid library may contain all or substantially all of the complexity of the genome. The term "substantially all" in this context actually refers to the possibility that there may be some undesired loss of genome complexity during the initial steps of the procedure. The methods described herein are also useful when the nucleic acid library is a portion of a genome, for example, when the complexity of the genome is reduced by design. In some examples, any selected portion of the genome may be used with the methods described herein. For example, in certain embodiments, the entire exome or a subset thereof is isolated. In some examples, the library may contain at least 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% genomic DNA. In some examples, the library may consist of cDNA copies of genomic DNA that contain at least 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, or 5% genomic DNA. In certain examples, the amount of nucleic acid used to generate a nucleic acid library can be less than 5 micrograms, less than 1 microgram, less than 500 ng, less than 200 ng, less than 100 ng, less than 50 ng, less than 10 ng, less than 5 ng, or less than 1 ng.
[0160] In some examples, a library (e.g., a nucleic acid library) comprises a collection of nucleic acid molecules. As described herein, the nucleic acid molecules of the library can include target nucleic acid molecules (e.g., tumor nucleic acid molecules, reference nucleic acid molecules, and / or control nucleic acid molecules, also referred to herein as first, second, and / or third nucleic acid molecules, respectively). The nucleic acid molecules of the library can be derived from a single subject or individual. In some examples, a library can include nucleic acid molecules from two or more subjects (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30 or more subjects). For example, two or more libraries from different subjects can be combined to form a library with nucleic acid molecules from two or more subjects (wherein the nucleic acid molecules from each subject are optionally ligated to a unique sample barcode corresponding to the particular subject). In some examples, the subject is a human having or at risk of having cancer or a tumor.
[0161] In some examples, a library (or a portion thereof) may include one or more subgenomic intervals. In some examples, a subgenomic interval may be a single nucleotide position, e.g., a nucleotide position where a variant at that position is associated (positively or negatively) with a tumor phenotype. In some examples, a subgenomic interval includes two or more nucleotide positions. Such examples include a sequence of at least 2, 5, 10, 50, 100, 150, 250, or more than 250 nucleotide positions in length. A subgenomic interval may include, for example, one or more entire genes (or portions thereof), one or more exons or coding sequences (or portions thereof), one or more introns (or portions thereof), one or more microsatellite regions (or portions thereof), or any combination thereof. A subgenomic interval may include all or a portion of a fragment of a naturally occurring nucleic acid molecule, e.g., a genomic DNA molecule. For example, a subgenomic interval may correspond to a fragment of genomic DNA that is subjected to a sequencing reaction. In some examples, a subgenomic interval is a contiguous sequence from a genomic source. In some instances, the subgenomic interval comprises sequences that are not contiguous in the genome, for example, a subgenomic interval in a cDNA may comprise an exon-exon junction formed as a result of splicing. In some instances, the subgenomic interval comprises a tumor nucleic acid molecule. In some instances, the subgenomic interval comprises a non-tumor nucleic acid molecule.
[0162] Targeting loci for analysis The methods described herein may be used in combination with, or as part of, a method for evaluating a set of intervals of interest (e.g., target sequences) from, for example, a set of genomic loci (e.g., loci or fragments thereof), as described herein.
[0163] In some examples, the set of genomic loci evaluated by the disclosed methods includes multiple, e.g., genes, that, in mutant form, are associated with an effect on cell division, proliferation or survival, or are associated with cancer, e.g., a cancer described herein.
[0164] In some examples, the set of loci evaluated by the disclosed methods includes at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, or more than 100 loci.
[0165] In some examples, the selected locus (also referred to herein as a target locus or target sequence) or a fragment thereof may comprise an interval of interest, including a non-coding sequence, a coding sequence, an intragenic region, or an intergenic region of the genome of interest. For example, the interval of interest may include a non-coding sequence or a fragment thereof (e.g., a promoter sequence, an enhancer sequence, a 5' untranslated region (5'UTR), a 3' untranslated region (3'UTR), or a fragment thereof), a coding sequence of a fragment thereof, an exon sequence or a fragment thereof, an intron sequence or a fragment thereof.
[0166] Target Capture Reagents The methods described herein may include contacting a nucleic acid library with a plurality of target capture reagents to select and capture a plurality of specific target sequences (e.g., gene sequences or fragments thereof) for analysis. In some examples, a target capture reagent (i.e., a molecule that binds to a target molecule, thereby allowing capture of the target molecule) is used to select the interval of interest to be analyzed. For example, the target capture reagent may be a bait molecule, e.g., a nucleic acid molecule (e.g., a DNA molecule or an RNA molecule), that can hybridize to (i.e., be complementary to) a target molecule, thereby allowing capture of the target nucleic acid. In some examples, the target capture reagent, e.g., a bait molecule (or bait sequence), is a capture oligonucleotide (or capture probe). In some examples, the target nucleic acid is a genomic DNA molecule, an RNA molecule, a cDNA molecule derived from an RNA molecule, a microsatellite DNA sequence, or the like. In some examples, the target capture reagent is suitable for solution-phase hybridization to the target. In some examples, the target capture reagent is suitable for solid-phase hybridization to the target. In some instances, the target capture reagent is suitable for both solution phase and solid phase hybridization to the target. The design and construction of target capture reagents are described in more detail, for example, in International Patent Application Publication No. WO2020 / 236941, the entire contents of which are incorporated herein by reference.
[0167] The methods described herein provide optimized sequencing of multiple genomic loci (e.g., genes or gene products (e.g., mRNA), microsatellite loci, etc.) from samples (e.g., cancer tissue specimens, liquid biopsy samples, etc.) from one or more subjects by appropriate selection of target capture reagents to select the target nucleic acid molecules to be sequenced. In some examples, a target capture reagent may hybridize to a specific target locus, e.g., a specific target locus or fragment thereof. In some examples, a target capture reagent may hybridize to a specific group of target loci, e.g., a specific group of loci or fragments thereof. In some examples, multiple target capture reagents may be used, including a mix of target-specific and / or group-specific target capture reagents.
[0168] In some examples, the number of target capture reagents (e.g., bait molecules) in a plurality of target capture reagents (e.g., bait set) contacted with a nucleic acid library to capture a plurality of target sequences for nucleic acid sequencing is greater than 10, greater than 50, greater than 100, greater than 200, greater than 300, greater than 400, greater than 500, greater than 600, greater than 700, greater than 800, greater than 900, greater than 1,000, greater than 1,250, greater than 1,500, greater than 1,750, greater than 2,000, greater than 3,000, greater than 4,000, greater than 5,000, greater than 10,000, greater than 25,000, or greater than 50,000.
[0169] In some examples, the total length of the target capture reagent sequence can be between about 70 nucleotides and 1000 nucleotides. In one example, the length of the target capture reagent is between about 100 and 300 nucleotides, 110 and 200 nucleotides, or 120 and 170 nucleotides in length. In addition to the above, intermediate oligonucleotide lengths of about 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 300, 400, 500, 600, 700, 800, and 900 nucleotides in length can be used in the methods described herein. In some embodiments, oligonucleotides of about 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220 or 230 bases may be used.
[0170] In some examples, each target capture reagent sequence may include (i) a target-specific capture sequence (e.g., a locus- or microsatellite locus-specific complementary sequence), (ii) an adapter, primer, barcode, and / or unique molecular identifier sequence, and (iii) a universal tail at one or both ends. As used herein, the term "target capture reagent" may refer to a target-specific target capture sequence or an entire target capture reagent oligonucleotide that includes a target-specific target capture sequence.
[0171] In some examples, the target-specific capture sequence in the target capture reagent is about 40 nucleotides to 1000 nucleotides in length. In some examples, the target-specific capture sequence is about 70 nucleotides to 300 nucleotides in length. In some examples, the target-specific sequence is about 100 nucleotides to 200 nucleotides in length. In still other examples, the target-specific sequence is about 120 nucleotides to 170 nucleotides in length, typically 120 nucleotides in length. In addition to the above, target-specific sequences of intermediate lengths, for example, about 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 300, 400, 500, 600, 700, 800, and 900 nucleotides in length, as well as target-specific sequences of lengths between the above lengths, can also be used in the methods described herein.
[0172] In some examples, target capture reagent can be designed to select the target section that contains one or more rearrangements, for example, the intron that contains genomic rearrangement.In such examples, target capture reagent is designed to mask repetitive sequences to improve selection efficiency.In these examples where rearrangement has known linking sequence, complementary target capture reagent can be designed to linking sequence to improve selection efficiency.
[0173] In some examples, the disclosed methods may include the use of target capture reagents designed to capture two or more different target categories, with each category having a different target capture reagent design strategy. In some examples, the hybridization-based capture methods and target capture reagent compositions disclosed herein provide capture and homogenous coverage of a target sequence set, while minimizing coverage of genomic sequences outside the targeted sequence set. In some examples, the target sequence may include an entire exome of genomic DNA or a selected subset thereof. In another example, the target sequence may include a large chromosomal region (e.g., an entire chromosome arm). The methods and compositions disclosed herein provide different target capture reagents to achieve different sequencing depths and coverage patterns for a complex target nucleic acid sequence set.
[0174] Typically, DNA molecules are used as target capture reagent sequences, but RNA molecules can also be used. In some instances, DNA molecule target capture reagents can be single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA). In some instances, RNA-DNA duplexes are more stable than DNA-DNA duplexes, and therefore potentially provide better capture of nucleic acids.
[0175] In some examples, the disclosed methods include providing a selected set of nucleic acid molecules (e.g., library catch) captured from one or more nucleic acid libraries. For example, the methods can include providing one or more nucleic acid libraries, each containing a plurality of nucleic acid molecules (e.g., a plurality of target nucleic acid molecules and / or reference nucleic acid molecules) extracted from one or more samples from one or more subjects, contacting the one or more libraries (e.g., in a solution-based hybridization reaction) with one, two, three, four, five, or more than five target capture reagents (e.g., oligonucleotide target capture reagents) to form a hybridization mixture containing a plurality of target capture reagent / nucleic acid molecule hybrids, and separating the plurality of target capture reagent / nucleic acid molecule hybrids from the hybridization mixture, e.g., by contacting the hybridization mixture with a binding entity that allows separation of the plurality of target capture reagent / nucleic acid molecule hybrids from the hybridization mixture, thereby providing a library catch (e.g., a subgroup of selected or enriched nucleic acid molecules from one or more libraries).
[0176] In some examples, the disclosed methods can further include amplifying the library catch (e.g., by performing PCR). In other examples, the library catch is not amplified.
[0177] In some examples, the target capture reagent may be part of a kit, which may include instructions, standards, buffers or enzymes or other reagents as needed.
[0178] Hybridization conditions As noted above, the methods disclosed herein may include contacting a library (e.g., a nucleic acid library) with a plurality of target capture reagents to contact selected library target nucleic acid sequences (i.e., library catch). The contacting step may be performed, for example, by solution-based hybridization. In some examples, the method includes repeating the hybridization step for one or more additional solution-based hybridizations. In some examples, the method further includes subjecting the library catch to one or more additional solution-based hybridizations with the same or a different set of target capture reagents.
[0179] In some examples, the contacting step is performed using a solid support, e.g., an array. Suitable solid supports for hybridization are described, for example, in Albert, TJ et al. (2007) Nat. Methods 4(11):903-5, Hodges, E. et al. (2007) Nat. Genet. 39(12):1522-7, and Okou, DT et al. (2007) Nat. Methods 4(11):907-9, the contents of which are incorporated herein by reference in their entirety.
[0180] Hybridization methods that can be adapted for use in the methods herein are described in the art, for example, as described in International Patent Application Publication No. 2012 / 092426. Methods for hybridizing target capture reagents to multiple target nucleic acids are described in more detail, for example, in International Patent Application Publication No. WO2020 / 236941, the entire contents of which are incorporated herein by reference.
[0181] Sequencing methods The methods and systems disclosed herein may be used in conjunction with, or as part of, a method or system for sequencing nucleic acids (e.g., a next-generation sequencing system) to generate multiple sequence reads that overlap one or more loci within a subgenomic interval in a sample, thereby, for example, determining gene allele sequences at multiple loci. "Next-generation sequencing" (or "NGS") as used herein may also be referred to as "massively parallel sequencing," which involves the determination of the nucleotide sequence of individual nucleic acid molecules (e.g., in single-molecule sequencing) or clonally amplified proxies of individual nucleic acid molecules in a high-throughput manner (e.g., in 10 3 , 10 4 , 10 5 or 10 5 This refers to any sequencing method in which multiple molecules are sequenced simultaneously.
[0182] Next generation sequencing methods are known in the art and are described, for example, in Metzker, M. (2010) Nature Biotechnology Reviews 11:31-46, which is incorporated herein by reference. Other examples of sequencing methods suitable for use in implementing the methods and systems disclosed herein are described, for example, in International Patent Application Publication No. WO2012 / 092426. In some examples, sequencing may include, for example, whole genome sequencing (WGS), whole exome sequencing, targeted sequencing, or direct sequencing. In some examples, sequencing may be performed, for example, using Sanger sequencing.
[0183] The disclosed methods and systems may be implemented using a sequencing platform, such as Roche 454, Illumina Solexa, ABI-SOLiD, ION Torrent, Complete Genomics, Pacific Bioscience, Helicos, and / or Polonator platforms. In some examples, the sequencing may include Illumina MiSeq sequencing. In some examples, the sequencing may include Illumina HiSeq sequencing. In some examples, the sequencing may include Illumina NovaSeq sequencing. Optimized methods for sequencing multiple target genomic loci in nucleic acid extracted from a sample are described in more detail, for example, in International Patent Application Publication No. WO2020 / 236941, the entire contents of which are incorporated herein by reference.
[0184] In certain examples, the disclosed methods include the steps of: (a) obtaining a library from a sample comprising a plurality of normal and / or tumor nucleic acid molecules; (b) simultaneously or sequentially contacting the library with a plurality of 1, 2, 3, 4, 5, or more than 5 target capture reagents under conditions that permit hybridization of the target capture reagents to the target nucleic acid molecules, thereby providing a selected set of captured normal and / or tumor nucleic acid molecules (i.e., library catch); and (c) isolating the selected subset of nucleic acid molecules (e.g., library catch) by, for example, contacting the hybridization mixture with a binding entity that permits separation of the target capture reagent / nucleic acid molecule hybrids from the hybridization mixture. (d) sequencing the library catch to obtain a plurality of reads (e.g., sequence reads) that overlap with one or more intervals of interest (e.g., one or more target sequences) from the library catch that may contain mutations (or alterations), e.g., mutant sequences that contain somatic or germline mutations; (e) aligning the sequence reads using an alignment method described elsewhere herein; and / or (f) assigning nucleotide values to nucleotide positions within the intervals of interest from one or more of the plurality of sequence reads (e.g., calling mutations using a Bayesian method or other method described herein).
[0185] In some examples, obtaining sequence reads for one or more intervals of interest may include sequencing at least 1, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, at least 650, at least 700, at least 750, at least 800, at least 850, at least 900, at least 950, at least 1,000, at least 1,250, at least 1,500, at least 1,750, at least 2,000, at least 2,250, at least 2,500, at least 2,750, at least 3,000, at least 3,500, at least 4,000, at least 4,500, or at least 5,000 loci, e.g., genomic loci, loci, microsatellite loci, etc. In some examples, obtaining sequence reads for one or more target intervals can include sequencing the target intervals for any number of loci within the ranges described in this paragraph, for example, at least 2,850 loci.
[0186] In some examples, obtaining sequence reads for one or more intervals of interest includes sequencing the intervals of interest using a sequencing method that provides a sequence read length (or average sequence read length) of at least 20 bases, at least 30 bases, at least 40 bases, at least 50 bases, at least 60 bases, at least 70 bases, at least 80 bases, at least 90 bases, at least 100 bases, at least 120 bases, at least 140 bases, at least 160 bases, at least 180 bases, at least 200 bases, at least 220 bases, at least 240 bases, at least 260 bases, at least 280 bases, at least 300 bases, at least 320 bases, at least 340 bases, at least 360 bases, at least 380 bases, or at least 400 bases. In some examples, obtaining sequence reads for one or more intervals of interest can include sequencing the intervals of interest using a sequencing method that provides a sequence read length (or average sequence read length) of any number of bases within the ranges described in this paragraph, for example, a sequence read length (or average sequence read length) of 56 bases.
[0187] In some examples, obtaining sequence reads for one or more target intervals may include sequencing at an average coverage (or depth) of at least 100x or more. In some examples, obtaining sequence reads for one or more target intervals may include sequencing at an average coverage (or depth) of at least 100x, at least 150x, at least 200x, at least 250x, at least 500x, at least 750x, at least 1,000x, at least 1,500x, at least 2,000x, at least 2,500x, at least 3,000x, at least 3,500x, at least 4,000x, at least 4,500x, at least 5,000x, at least 5,500x, or at least 6,000x or more. In some examples, obtaining sequence reads for one or more target intervals may include sequencing at an average coverage (or depth) having any value within the range of values described in this paragraph, for example, at least 160x.
[0188] In some examples, obtaining sequence reads for one or more target intervals includes sequencing at an average sequencing depth having any value ranging from at least 100x to at least 6,000x for more than about 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% of the sequenced loci. For example, in some examples, obtaining reads for a target interval includes sequencing at an average sequencing depth of at least 125x for at least 99% of the sequenced loci. As another example, in some examples, obtaining reads for a target interval includes sequencing at an average sequencing depth of at least 4,100x for at least 95% of the sequenced loci.
[0189] In some examples, the relative abundance of nucleic acid species in a library can be estimated by counting the relative number of occurrences of their cognate sequences in the data generated by the sequencing experiment (e.g., the number of sequence reads for a given cognate sequence).
[0190] In some examples, the disclosed methods and systems provide nucleotide sequences for a set of subject intervals (e.g., loci) as described herein. In certain instances, the sequences are provided without the use of methods that include matched normal controls (e.g., wild-type controls) and / or matched tumor controls (e.g., primary vs. metastatic).
[0191] In some examples, as used herein, the level of sequencing depth (e.g., X-fold level of sequencing depth) refers to the number of reads (e.g., unique reads) obtained after detection and removal of duplicate reads (e.g., PCR duplicate reads). In other examples, duplicate reads are evaluated, for example, to aid in the detection of copy number alterations (CNAs).
[0192] alignment Alignment is the process of matching reads to a location, e.g., a genomic location or locus. In some examples, NGS reads can be aligned to a known reference sequence (e.g., a wild-type sequence). In some examples, NGS reads can be de novo assembled. Methods of sequence alignment for NGS reads are described, for example, in Trapnell, C. and Salzberg, SL Nature Biotech., 2009, 27:455-457. Examples of de novo sequence assembly are described, for example, in Warren R. et al., Bioinformatics, 2007, 23:500-501, Butler J. et al., Genome Res., 2008, 18:810-820, and Zerbino DR and Birney E., Genome Res., 2008, 18:821-829. Optimization of sequence alignment is described in the art, for example, as described in International Patent Application Publication No. 2012 / 092426. Additional description of sequence alignment methods is described in more detail, for example, in International Patent Application Publication No. 2020 / 236941, the entire contents of which are incorporated herein by reference.
[0193] Misalignment (e.g., placement of base pairs from short reads at incorrect locations in the genome), for example, misalignment of reads due to sequence context (e.g., presence of repetitive sequences) around the actual cancer mutation can lead to reduced sensitivity of mutation detection because alternate allele reads can be shifted from the histogram peak of alternate allele reads. Other examples of sequence contexts that can cause misalignment include short tandem repeats, interspersed repetitive sequences, low complexity regions, insertion-deletions (indels), and paralogs. When problematic sequence situations arise in the absence of actual mutations, misalignment can introduce artifactual reads of "mutated" alleles by misplacing reads of the actual reference genome base sequence. Because mutation calling algorithms for multigene analysis must be sensitive to even low abundance mutations, sequence misalignment can increase false positive discovery rates and / or reduce specificity.
[0194] In some examples, the methods and systems disclosed herein may integrate the use of multiple individually tailored alignment methods or algorithms to optimize base calling performance in sequencing methods, particularly those that rely on massively parallel sequencing of multiple diverse genetic events at multiple diverse genomic loci. In some examples, the disclosed methods and systems may include the use of one or more global alignment algorithms. In some examples, the disclosed methods and systems may include the use of one or more local alignment algorithms.Examples of alignment algorithms that may be used include, but are not limited to, the Burrows-Wheeler Alignment (BWA) software bundle (see, e.g., Li, et al. (2009), "Fast and Accurate Short Read Alignment with Burrows-Wheeler Transform", Bioinformatics 25:1754-60; Li, et al. (2010), Fast and Accurate Long-Read Alignment with Burrows-Wheeler Transform", Bioinformatics epub. PMID:20080505), the Smith-Waterman algorithm (see, e.g., Smith, et al. (1981), "Identification of Common Molecular Subsequences", J. Molecular Biology 147(1):195-197), the Striped Smith-Waterman algorithm (see, e.g., Farrar (2007), "Striped Smith-Waterman Speeds Database Searches Six Times Over Other SIMD Examples of such algorithms include the Needleman-Wunsch algorithm (see, for example, "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. Molecular Biology 48(3):443-53), or any combination thereof.
[0195] In some examples, the methods and systems disclosed herein may also include the use of a sequence assembly algorithm, such as the Arachne sequencing assembly algorithm (see, e.g., Batzoglou, et al. (2002), "ARACHNE: A Whole-Genome Shotgun Assembler", Genome Res. 12:177-189).
[0196] In some examples, the alignment method used to analyze the sequence reads is not individually customized or adjusted for the detection of different variants (e.g., point mutations, insertions, deletions, etc.) at different genomic loci. In some examples, different alignment methods are used to analyze the reads that are individually customized or adjusted for the detection of at least a subset of the different variants detected at different genomic loci. In some examples, different alignment methods are used to analyze the reads that are individually customized or adjusted for the detection of each different variant at different genomic loci. In some examples, the adjustments can be a function of one or more of: (i) the locus to be sequenced (e.g., a gene locus, a microsatellite locus, or other interval of interest), (ii) the tumor type associated with the sample, (iii) the variant to be sequenced, or (iv) the characteristics of the sample or subject. The selection or use of alignment conditions that are individually adjusted to several specific intervals of interest to be sequenced allows for the optimization of speed, sensitivity, and specificity. This method is particularly effective when the alignment of reads to a relatively large number of diverse intervals of interest is optimized. In some examples, the methods include the combined use of an alignment method optimized for the rearrangement and another alignment method optimized for a target interval not associated with the rearrangement.
[0197] In some examples, the methods disclosed herein further include selecting or using an alignment method for analyzing, e.g., aligning, the sequence reads, where the alignment method is a function of, selected in response to, or optimized for one or more of: (i) the tumor type, e.g., the tumor type in the sample; (ii) the location (e.g., locus) of the interval of interest to be sequenced; (iii) the type of variant (e.g., point mutation, insertion, deletion, substitution, copy number variation (CNV), rearrangement, or fusion) within the interval of interest to be sequenced; (iv) the site (e.g., nucleotide position) being analyzed; (v) the type of sample (e.g., a sample described herein); and / or (vi) the flanking sequences within or near the interval of interest being evaluated (e.g., according to their expected propensity for misalignment of the interval of interest due to the presence of repetitive sequences within or near the interval of interest).
[0198] In some examples, the methods disclosed herein allow for fast and efficient alignment of troublesome reads, e.g., reads with rearrangements.Thus, in some examples where the reads for the target interval include nucleotide positions with rearrangements, e.g., translocations, the method can include using an alignment method that is appropriately adjusted and includes: (i) selecting a rearrangement reference sequence for alignment with the read, where the rearrangement reference sequence aligns with the rearrangement (in some examples, the reference sequence is not identical to the genomic rearrangement), and (ii) comparing, e.g., aligning, the read with the rearrangement reference sequence.
[0199] In some examples, alternative methods can be used to align problematic reads. These methods are particularly effective when alignment of reads to a relatively large number of diverse target intervals is optimized. As an example, a method of analyzing a sample can include (i) performing a comparison (e.g., an alignment comparison) of reads using a first set of parameters (e.g., using a first mapping algorithm or by comparison with the first reference sequence) to determine whether the reads meet a first alignment criterion (e.g., the reads can be aligned with the first reference sequence, e.g., with less than a certain number of mismatches); and (ii) performing a second alignment comparison using a second set of parameters if the reads do not meet the first alignment criterion (e.g., using a second reference sequence). (iii) optionally determining whether the read satisfies a second criterion (e.g., the read can be aligned with the second reference sequence, e.g., with less than a certain number of mismatches), where a second set of parameters includes use of the second reference sequence that is more likely to result in alignment of the read to a variant (e.g., a rearrangement, insertion, deletion, or translocation), e.g., compared to the first set of parameters.
[0200] In some examples, alignment of sequence data in the disclosed methods may be combined with mutation calling methods described elsewhere herein. As discussed herein, reduced sensitivity for detecting actual mutations may be addressed by assessing (manually or in an automated manner) the quality of the alignment around the expected mutation site of the gene or genomic locus (e.g., locus) being analyzed. In some examples, the site to be assessed may be obtained from a database of human genomes (e.g., HG19 human reference genome) or cancer mutations (e.g., COSMIC). Regions identified as problematic may be repaired, for example, by alignment optimization (or realignment) using a slower but more accurate alignment algorithm such as Smith-Waterman alignment, using an algorithm selected to give better performance in the relevant sequence context. If a general alignment algorithm cannot ameliorate the problem, customized alignment approaches can be created by, for example, adjusting the maximum different mismatch penalty parameters for genes that are likely to contain substitutions, adjusting specific mismatch penalty parameters based on specific mutation types that are common to certain tumor types (e.g., C→T in melanoma), or adjusting specific mismatch penalty parameters based on specific mutation types that are common to certain sample types (e.g., substitutions that are common to FFPE).
[0201] The loss of specificity (increased false positive rate) of the evaluated target interval due to misalignment can be assessed by manual or automated inspection of all variant calls in the sequencing data. Regions found to be prone to false variant calls due to misalignment can be subjected to alignment improvements as discussed above. If algorithmic improvements are not possible, "variations" from problematic regions can be sorted or screened from a panel of target loci.
[0202] Mutation Call Base calling refers to the raw output of a sequencing device, e.g., the determined sequence of nucleotides in an oligonucleotide molecule. Mutation calling refers to the process of selecting a nucleotide value, e.g., A, G, T, or C, for a given nucleotide position being sequenced. Typically, a sequence read (or base call) for a position will provide more than one value, e.g., some reads will indicate T and some will indicate G. Mutation calling is the process of assigning the correct nucleotide value, e.g., one of those values, to a sequence. Although referred to as a "mutation" call, it can be applied to assign a nucleotide value to any nucleotide position, e.g., a position corresponding to a mutant allele, a wild type allele, an allele not characterized as mutant or wild type, or a position not characterized by variability.
[0203] In some examples, the disclosed methods may include the use of customized or tuned variant calling algorithms or parameters to optimize performance when applied to sequencing data, particularly in methods that rely on massively parallel sequencing of multiple diverse genetic events at multiple diverse genomic loci (e.g., gene loci, microsatellite regions, etc.) in a sample, e.g., from a subject with cancer. Optimization of variant calling has been described in the art, e.g., as described in International Patent Application Publication No. WO 2012 / 092426.
[0204] Methods for variant calling can include one or more of the following: making independent calls based on information at each position in the reference sequence (e.g., examining sequence reads; examining base calls and quality scores; calculating the probability of observed bases and quality scores given potential genotypes; and assigning genotypes (e.g., using Bayes' rule); removing false positives (e.g., using a depth threshold to reject SNPs with read depths much lower or higher than expected; local refinement to remove false positives due to small indels); and performing linkage disequilibrium (LD) / imputation-based analysis to refine the calls.
[0205] The formula used to calculate the genotype likelihood associated with a particular genotype and location is described, for example, in Li H. and Durbin R. Bioinformatics, 2010;26(5):589-95. A priori predictions for a particular mutation in a particular cancer type can be used when evaluating samples from that cancer type. Such probabilities can be obtained from public databases of cancer mutations, such as Catalogue of Somatic Mutation in Cancer (COSMIC), HGMD (Human Gene Mutation Database), The SNP Consortium, Breast Cancer Mutation Data Base (BIC) and Breast Cancer Gene Database (BCGD).
[0206] Examples of LD / imputation-based analysis are described, for example, in Browning, B. L. and Yu, Z. Am. J. Hum. Genet. 2009, 85(6):847-61. Examples of low coverage SNP calling methods are described, for example, in Li, Y., et al., Annu. Rev. Genomics Hum. Genet. 2009, 10:387-406.
[0207] After alignment, detection of substitutions can be performed using a calling method (e.g., a Bayesian mutation calling method), which is applied to each base in each of the target intervals, e.g., exons of the gene or other locus being evaluated, and the presence of alternative alleles is observed. This method compares the probability of observing read data in the presence of a mutation to the probability of observing read data in the presence of base calling errors alone. If this comparison is sufficiently strong in support of the presence of a mutation, the mutation can be called.
[0208] The advantage of a Bayesian mutation detection approach is that the comparison of the probability of the presence of a mutation versus the probability of a base calling error alone can be weighted by a prior expectation of the presence of the mutation at that site. If several reads of alternative alleles are observed at a site that is frequently mutated for a given cancer type, the presence of the mutation can be called with confidence even if the amount of evidence for the mutation does not meet the usual threshold. This flexibility can then be used to increase the detection sensitivity for rarer mutations / lower purity samples or to make the test more robust against reduced read coverage. The likelihood of a random base pair in the genome being mutated in cancer is approximately 1e-6. For example, the likelihood of a specific mutation occurring at many sites in a typical polygenic cancer genome panel can be orders of magnitude higher. These likelihoods can be derived from public databases of cancer mutations (e.g., COSMIC).
[0209] Indel calling is the process of finding bases in sequencing data that differ from a reference sequence by insertion or deletion, typically with associated confidence score or statistical evidence indicator. Methods of indel calling can include identifying candidate indels, calculating genotype likelihood by local realignment, and performing LD-based genotype inference and calling. Typically, Bayesian methods are used to obtain potential indel candidates, and then these candidates are tested with reference sequences in a Bayesian framework.
[0210] Algorithms for generating candidate indels are described, for example, in McKenna, A., et al., Genome Res. 2010; 20(9): 1297-303, Ye, K., et al., Bioinformatics, 2009; 25(21): 2865-71, Lunter, G., and Goodson, M., Genome Res. 2011; 21(6): 936-9, and Li, H., et al. (2009), Bioinformatics 25(16): 2078-9.
[0211] Methods for generating indel calling and individual-level genotype likelihood include, for example, the Dindel algorithm (Albers CA et al., Genome Res. 2011; 21(6): 961-73). For example, a Bayesian EM algorithm can be used to analyze reads, make initial indel calls, and generate genotype likelihoods for each candidate indel, followed by imputing genotypes using, for example, QCALL (Le SQ and Durbin R. Genome Res. 2011; 21(6): 952-60). Parameters such as prior expectation of observing an indel can be adjusted (e.g., increased or decreased) based on the size or location of the indel.
[0212] Methods have been developed that address limited deviations from 50% or 100% allele frequency for the analysis of cancer DNA. (See, e.g., SNVMix - Bioinformatics. 2010 March 15;26(6):730-736.) However, the methods disclosed herein allow for frequencies (or allele fractions) ranging from 1% to 100% (i.e., allele fractions ranging from 0.01 to 1.0), and in particular, consideration of the possible presence of mutant alleles at levels below 50%. This approach is particularly important for the detection of mutations in, for example, low-purity FFPE samples of native (multiclonal) tumor DNA.
[0213] In some examples, the variant calling method used to analyze the sequence reads is not individually customized or tuned for the detection of different variants at different genomic loci. In some examples, a different variant calling method is used that is individually customized or fine-tuned for at least a subset of the different variants detected at different genomic loci. In some examples, a different variant calling method is used that is individually customized or fine-tuned for each different variant detected at each different genomic locus. The customization or tuning can be based on one or more of the factors described herein, such as the type of cancer in the sample, the gene or locus in which the target interval to be sequenced is located, or the variant to be sequenced. This selection or use of a variant calling method that is individually customized or fine-tuned for the number of target intervals to be sequenced allows for optimization of the speed, sensitivity, and specificity of variant calling.
[0214] In some examples, a nucleotide value is assigned to a nucleotide position of each of the X unique target intervals using a unique variant calling method, where X is at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 1500, at least 2000, at least 2500, at least 3000, at least 3500, at least 4000, at least 4500, at least 5000 or more. The calling methods can be different and thereby unique, for example, by relying on different Bayesian priors.
[0215] In some instances, assigning the nucleotide value is a function of a value that is or represents an expected value prior to observing (e.g., in the literature) reads that exhibit a variant, e.g., mutation, at that nucleotide position in a tumor of the type.
[0216] In some examples, the method includes assigning nucleotide values (e.g., mutation calls) for at least 10, 20, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1,000 nucleotide positions, where each assignment is a function of a unique (as opposed to other assigned values) value that is or represents an expected value prior (e.g., in the literature) of observing reads that indicate a variant, e.g., a mutation, at that nucleotide position in a tumor of the type.
[0217] In some examples, assigning the nucleotide value is a function of a set of values that represent the probability of observing a read exhibiting the variant at that nucleotide position if the variant is present in the sample at a particular frequency (e.g., 1%, 5%, 10%, etc.) and / or if the variant is not present (e.g., observed in the read due to base calling errors only).
[0218] In some examples, a variant calling method described herein may include: (a) obtaining, for a nucleotide position in each of the X intervals of interest, (i) a first value that is or represents an expectation prior to (e.g., literature) observing a variant, e.g., a read exhibiting a mutation, at that nucleotide position in a tumor of type X; and (ii) a second set of values that represent the likelihood of observing a read exhibiting the variant at that nucleotide position if the variant is present in the sample at a certain frequency (e.g., 1%, 5%, 10%, etc.) and / or if the variant is not present (e.g., observed in a read due to base calling error alone); and (b) in response to the values, assigning to each of the nucleotide positions a nucleotide value from the read (e.g., calling a variant) by weighting a comparison between the values in the second set using the first value, e.g., by a Bayesian method described herein, thereby analyzing the sample.
[0219] Further description of variant calling methods is described in more detail, for example, in International Patent Application Publication No. WO 2020 / 236941, the entire contents of which are incorporated herein by reference.
[0220] System for CNA detection and invocation Also disclosed herein is a system designed to implement any of the disclosed methods. The system may comprise, for example, one or more processors and a memory unit communicatively coupled to the one or more processors and configured to store instructions, which, when executed by the one or more processors, cause the system to: receive, at the one or more processors, sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject; generate, using the one or more processors, minor allele coverage ratios and major allele coverage ratios for a plurality of loci; segment, using the one or more processors, the genome into a plurality of genomic segments (e.g., based on the minor allele coverage ratio, the major allele coverage ratio, or a total coverage ratio); and generate, using the one or more processors, a plurality of genomic segments. and generating copy number grid model input data, the copy number grid model input data including (i) a difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio, for loci of the plurality of loci, fitting a plurality of copy number grid models including allowed copy number states to the copy number model input data, selecting a copy number grid model from the plurality of copy number grid models, and assigning copy number states for at least a portion of the plurality of genomic segments based on the selected copy number grid model, using the one or more processors. Different copy number grid models in the plurality of copy number grid models may be initialized using different initial tumor purity estimates and tumor ploidy estimates.
[0221] In some embodiments, the instructions that cause the system to select the selected copy number grid model include instructions that cause the system to determine, for each genome segment, a distribution of copy number grid model input data; identify, for each genome segment, a distance between the distribution and the closest copy number state; and determine an overall model fit score based on the average distance across multiple genome segments.
[0222] In some embodiments, the instructions to fit the allowed copy number states to the copy number grid model input data include instructions to cause the system to fit the allowed copy number states to the copy number grid model input data based on an initial tumor purity estimate and an initial tumor ploidy estimate, and iteratively: (a) assign a preliminary copy number to each segment of the plurality of segments; (b) determine an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignments; and (c) readjust the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate.
[0223] In some embodiments, the system further comprises an electronic display. The instructions, when executed by the one or more processors, may further include instructions that cause the system to overlay a selected copy number grid model with the converted coverage ratio data and present the overlay using an interface of the electronic display.
[0224] In some embodiments, the system further comprises instructions that, when executed by the one or more processors, cause the system to call copy number alterations for one or more loci or one or more genomic segments based on one or more assigned copy number states or total coverage ratio thresholds.
[0225] In some embodiments, the system further comprises instructions that, when executed by the one or more processors, cause the system to generate a report indicating the copy number status or called copy number changes for one or more genomic loci or one or more genomic segments. The instructions may further cause the system to transmit the report to the subject or a health care provider, for example, via a computer network or a peer-to-peer connection.
[0226] In some examples, the disclosed systems further include a sequencer, such as a next-generation sequencer (also called a massively parallel sequencer). Examples of next-generation (or massively parallel) sequencing platforms include, but are not limited to, Roche454, Illumina Solexa, ABI-SOLiD, ION Torrent, or Pacific Bioscience sequencing platforms.
[0227] In some examples, the disclosed systems can be used to call CNAs in any of the various samples described herein (e.g., a tissue sample, a biopsy sample, a blood sample, or a liquid biopsy sample from a subject).
[0228] In some examples, the plurality of loci for which sequencing data is processed to determine copy number alterations may include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more than 10 loci.
[0229] In some examples, the nucleic acid sequence data is obtained using next generation sequencing technology (also called massively parallel sequencing technology) with a read length of less than 400 bases, less than 300 bases, less than 200 bases, less than 150 bases, less than 100 bases, less than 90 bases, less than 80 bases, less than 70 bases, less than 60 bases, less than 50 bases, less than 40 bases, or less than 30 bases.
[0230] In some examples, determination of copy number alterations at one or more loci is used to select, initiate, adjust, or terminate treatment for cancer in a subject (e.g., patient) from which the sample was derived, as described elsewhere herein.
[0231] In some cases, the disclosed systems may further include sample processing and library preparation workstations, microplate handling robots, fluid dispensing systems, temperature control modules, environmental control chambers, additional data storage modules, data communication modules (e.g., Bluetooth, WiFi, intranet, or internet communication hardware and associated software), display modules, one or more local and / or cloud-based software packages (e.g., instrument / system control software packages, sequencing data analysis software packages), etc., or any combination thereof. In some cases, the systems may include or be part of a computer system or computer network described elsewhere herein.
[0232] A non-transitory computer readable storage medium, which may be part of the systems described herein or may be separate from such systems, may store one or more programs including instructions that, when executed by one or more processors, cause the system to: receive, with the one or more processors, sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject; generate, using the one or more processors, minor allele coverage ratios and major allele coverage ratios for the plurality of loci; segment, using the one or more processors, the genome into a plurality of genomic segments (e.g., based on the minor allele coverage ratios, major allele coverage ratios, or total coverage ratios); and generate, using the one or more processors, a sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject. generating copy number grid model input data including (i) a difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio, for loci of the plurality of loci, fitting, using one or more processors, a plurality of copy number grid models including allowed copy number states to the transformed coverage ratio data, the copy number grid model input data, selecting, using one or more processors, a selected copy number grid model from the plurality of copy number grid models, and assigning, using one or more processors, copy number states for at least a portion of the plurality of genomic segments based on the selected copy number grid model. Different copy number grid models in the plurality of copy number grid models may be initialized using different initial tumor purity estimates and tumor ploidy estimates.
[0233] In some embodiments of the non-transitory computer readable storage medium, the instructions that cause the system to select the selected copy number grid model include instructions that cause the system to determine, for each genome segment, a distribution of copy number grid model input data; identify, for each genome segment, a distance between the distribution and a closest copy number state; and determine an overall model fit score based on an average distance across multiple genome segments.
[0234] In some embodiments of the non-transitory computer-readable storage medium, the instructions to the system to fit allowed copy number states to the copy number grid model input data include instructions to cause the system to fit allowed copy number states to the copy number grid model input data based on an initial tumor purity estimate and an initial tumor ploidy estimate, and to iteratively: (a) assign a preliminary copy number to each segment of the plurality of segments; (b) determine an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignments; and (c) readapt the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate.
[0235] In some embodiments of the non-transitory computer-readable storage medium, the instructions, when executed by the one or more processors, further include instructions that cause the system to overlay the selected copy number grid model with the copy number grid model input data and present the overlay using an electronic display interface.
[0236] In some embodiments, the non-transitory computer readable storage medium further comprises instructions that, when executed by the one or more processors, cause the system to call copy number alterations for one or more loci or one or more genomic segments based on one or more assigned copy number states or total coverage ratio thresholds.
[0237] In some embodiments, the non-transitory computer readable storage medium further comprises instructions that, when executed by the one or more processors, cause the system to generate a report indicating the copy number status or called copy number changes for one or more genomic loci or one or more genomic segments. The insurgency may further cause the system to transmit the report to the subject or a health care provider, for example, via a computer network or a peer-to-peer connection.
[0238] Computer Systems and Networks FIG. 5 illustrates an example of a computing device or system according to an embodiment. The device 500 can be a host computer connected to a network. The device 500 can be a client computer or a server. As shown in FIG. 5, the device 500 can be any suitable type of microprocessor-based device, such as a personal computer, a workstation, a server, or a handheld computing device (portable electronic device, e.g., a phone or tablet). The device can include, for example, one or more processors 510, input devices 520, output devices 530, memory or storage devices 540, communication devices 560, and a nucleic acid sequencer 570. The software 550 resident in the memory or storage devices 540 can include, for example, an operating system, and software for performing the methods described herein. The input devices 520 and output devices 530 can generally correspond to those described herein and can be connectable to or integrated with the computer.
[0239] Input device 520 may be any suitable device that provides input, such as a touch screen, a keyboard or keypad, a mouse, or a voice recognition device. Output device 530 may be any suitable device that provides output, such as a touch screen, a tactile device, or a speaker. Input device 520 and output device 530 may be the same or different devices.
[0240] Storage 540 may be any suitable device that provides storage (e.g., electrical, magnetic, or optical memory, including RAM (volatile and non-volatile), cache, hard drive, or removable storage disk). Communications device 560 may include any suitable device that can send and receive signals over a network, such as a network interface chip or device. The components of a computer may be connected in any suitable manner, for example, via wired media (e.g., a physical system bus 580, an Ethernet connection, or any other wired transmission technology) or wirelessly (e.g., Bluetooth, Wi-Fi, or any other wireless technology).
[0241] The software modules 550 can be stored as executable instructions in the storage 540 and executed by the processor 510 and can include, for example, an operating system and / or processes that embody the functionality of the methods of the present disclosure (e.g., embodied in the devices described above).
[0242] The software module 550 may also be stored and / or transferred in any non-transitory computer-readable storage medium for use by or in connection with an instruction execution system, apparatus, or device (e.g., those described herein) that may fetch instructions associated with the software from and execute the instructions. In the context of the present disclosure, a computer-readable storage medium may be any medium, such as the storage 540, that may include or store processes for use by or in connection with an instruction execution system, apparatus, or device. Examples of computer-readable storage media may include memory units, such as hard drives, flash drives, and distribution modules that operate as a single functional unit. Also, the various processes described herein may be embodied as modules configured to operate according to the above embodiments and techniques. Moreover, while the processes may be shown and / or described separately, one skilled in the art will understand that the above processes may be routines or modules within other processes.
[0243] The software module 550 may also be propagated in any transmission medium for use by or in connection with an instruction execution system, apparatus, or device such as those mentioned above, which may fetch instructions associated with the software from the instruction execution system, apparatus, or device and execute the instructions. In the context of this disclosure, a transmission medium may be any medium that may communicate, propagate, or transmit transmission programming for use by or in connection with an instruction execution system, apparatus, or device. A transmission readable medium may include, but is not limited to, electronic, magnetic, optical, electromagnetic, or infrared wired or wireless propagation media.
[0244] The device 500 may be connected to a network (e.g., network 604 shown in FIG. 6 and / or described below), which may be any suitable type of interconnected communications system. The network may implement any suitable communications protocol and may be protected by any suitable security protocol. The network may include any suitable arrangement of network links that may implement transmission and reception of network signals, such as wireless network connections (T1 or T3 lines), cable networks, DSL, or telephone lines.
[0245] Device 500 may be implemented using any operating system, e.g., an operating system suitable for operating on a network. Software modules 550 may be written in any suitable programming language, such as C, C++, Java, or Python. In various embodiments, application software embodying functionality of the present disclosure may be deployed in different configurations (e.g., in a client / server arrangement, or via a web browser as a web-based application or web service). In some embodiments, the operating system is executed by one or more processors, e.g., processor 510.
[0246] The device 500 may further include a sequencer 570, which may be any suitable nucleic acid sequencing instrument.
[0247] 6 illustrates an example of a computing system according to one embodiment. In system 600, device 500 (e.g., as described above and illustrated in FIG. 5) is connected to a network 604, which is also connected to device 606. In some embodiments, device 606 is a sequencer. Exemplary sequencers include, but are not limited to, Roche / 454's Genome Sequencer (GS) FLX System, Illumina / Solexa's Genome Analyzer (GA), Illumina's HiSeq 2500, HiSeq 3000, HiSeq 4000, and NovaSeq 6000 sequencing systems, Life / APG's Support Oligonucleotide Ligation Detection (SOLiD) system, Polonator's G.007 system, HeliScope Gene sequencing system from Helicos BioSciences, or Pacific Biosciences' PacBio RS system.
[0248] The devices 500 and 606 can communicate using a suitable communication interface over a network 604, such as, for example, a local area network (LAN), a virtual private network (VPN), or the Internet. In some embodiments, the network 604 can be, for example, the Internet, an intranet, a virtual private network, a cloud network, a wired network, or a wireless network. The devices 500 and 606 can communicate partially or entirely over wireless or wired communications, such as Ethernet, IEEE 802.11b wireless, etc. Additionally, the devices 500 and 606 can communicate over a second network, such as, for example, a mobile / cellular network, using a suitable communication interface. The communication between the devices 500 and 606 can further include or communicate with various servers, such as a mail server, a mobile server, a media server, a telephone server, etc. In some embodiments, the devices 500 and 706 can communicate directly (instead of or in addition to communication over the network 604), such as, for example, Ethernet, IEEE 802.11b wireless, etc., or wired communications. In some embodiments, devices 500 and 606 communicate via communication 608, which may be a direct connection or may occur over a network (eg, network 604).
[0249] One or all of devices 500 and 606 generally include logic (e.g., http web server logic) accessed from local or remote databases or other sources of data and content or are programmed to format data to provide and / or receive information over network 604 in accordance with various examples described herein.
[0250] From the foregoing, it should be understood that, although specific embodiments of the disclosed method and system have been illustrated and described, various modifications can be made thereto and are contemplated herein. It is also not intended that the present invention be limited by the specific examples provided herein. Although the present invention has been described with reference to the above specification, the description and illustration of the preferred embodiments herein are not meant to be construed in a limiting sense. Furthermore, it should be understood that all aspects of the present invention are not limited to the specific depictions, configurations, or relative proportions set forth herein, which depend upon various conditions and variables. Various modifications in form and details of the embodiments of the present invention will be apparent to those skilled in the art. Thus, the present invention is also intended to encompass any such modifications, variations, and equivalents.
Claims
1. 1. A method comprising: providing a plurality of nucleic acid molecules obtained from a sample from a subject; ligating one or more adaptors onto one or more nucleic acid molecules from said plurality of nucleic acid molecules; amplifying the one or more ligated nucleic acid molecules from the plurality of nucleic acid molecules; capturing amplified nucleic acid molecules from the amplified nucleic acid molecules; sequencing, with a sequencer, the captured nucleic acid molecules to obtain a plurality of sequence reads representative of the captured nucleic acid molecules, thereby generating sequence read data for the genome of the sample; receiving, at one or more processors, the sequence read data; generating minor allele coverage ratios and major allele coverage ratios for a plurality of loci using the one or more processors; segmenting the genome into a plurality of genome segments using the one or more processors; generating, using the one or more processors, copy number grid model input data for loci of the plurality of loci, the copy number grid model input data including (i) a difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio; using the one or more processors to fit a plurality of copy number grid models including allowed copy number states to the copy number grid model input data; selecting a copy number grid model from the plurality of copy number grid models using the one or more processors; and and using the one or more processors, assigning copy number states for at least a portion of the plurality of genome segments based on the selected copy number grid model.
2. 2. The method of claim 1 , wherein the one or more adaptors comprise an amplification primer, a flow cell adaptor sequence, a substrate adaptor sequence, or a sample index sequence.
3. 3. The method of claim 1 or 2, wherein the captured nucleic acid molecules are captured from the amplified nucleic acid molecules by hybridization to one or more bait molecules.
4. 4. The method of claim 3, wherein the one or more bait molecules comprise one or more nucleic acid molecules, each nucleic acid molecule comprising a region complementary to a region of a captured nucleic acid molecule.
5. The method of any one of claims 1 to 4, wherein amplifying the nucleic acid molecule comprises performing a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique.
6. 6. The method of any one of claims 1 to 5, wherein the sequencing comprises the use of Massively Parallel Sequencing (MPS) technology, Whole Genome Sequencing (WGS), Whole Exome Sequencing, Targeted Sequencing, Direct Sequencing, or Sanger Sequencing technology.
7. 7. The method of claim 6, wherein the sequencing comprises massively parallel sequencing, and the massively parallel sequencing technology comprises next generation sequencing (NGS).
8. The method of any one of claims 1 to 7, wherein the sequencing comprises a next-generation sequencer.
9. 1. A method comprising: receiving, with one or more processors, sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject; generating minor allele coverage ratios and major allele coverage ratios for a plurality of loci using the one or more processors; segmenting the genome into a plurality of genome segments using the one or more processors; generating, using the one or more processors, copy number grid model input data for loci of the plurality of loci, the copy number grid model input data including (i) a difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio; using the one or more processors to fit a plurality of copy number grid models including allowed copy number states to the copy number grid model input data; selecting a copy number grid model from the plurality of copy number grid models using the one or more processors; and and using the one or more processors, assigning copy number states for at least a portion of the plurality of genome segments based on the selected copy number grid model.
10. The method of any one of claims 1 to 9, wherein the segmentation is based on the minor allele coverage ratio, the major allele coverage ratio, or a total coverage ratio.
11. selecting the copy number grid model from the plurality of copy number grid models; determining a distribution of the copy number grid model input data for each genome segment; identifying, for each genomic segment, the distance between said distribution and a closest copy number state; and determining an overall model fit score based on an average distance across the plurality of genome segments.
12. 12. The method of any one of claims 1 to 11, wherein different copy number grid models in the plurality of copy number grid models are initialized using different initial tumor purity and tumor ploidy estimates.
13. Fitting the plurality of copy number grid models to the copy number grid model input data comprises, for each copy number grid model, fitting the allowed copy number states of the copy number grid model to copy number grid model input data based on an initial tumor purity estimate and an initial tumor ploidy estimate; Iteratively, assigning a preliminary copy number to each genome segment of the plurality of genome segments; determining an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignments; and re-fitting the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate.
14. 14. The method of claim 12 or 13, wherein the initial tumor purity is constrained by a preselected lower tumor purity limit and a preselected upper tumor purity limit.
15. 15. The method of claim 14, wherein the preselected tumor purity lower limit is 0 and the preselected tumor purity upper limit is 1.
16. The method of any one of claims 12 to 15, wherein the initial tumor ploidy is constrained by a preselected lower tumor ploidy limit.
17. 17. The method of claim 16, wherein the preselected tumor ploidy lower limit is from about 1.1 to about 1.
5.
18. The method of any one of claims 12 to 17, wherein the initial tumor ploidy is constrained by a preselected upper tumor ploidy limit.
19. 20. The method of claim 18, wherein the preselected upper tumor ploidy limit is from about 6 to about 10.
20. 20. The method of any one of claims 1-19, wherein the assigned copy number state for each of the plurality of genome segments is a total copy number count for the genome segment, a minor allele copy number count for the genome segment, or a major allele copy number count for the genome segment.
21. 21. The method of any one of claims 1 to 20, wherein the segmentation is performed using a circular binary segmentation (CBS) method, a maximum likelihood method, a hidden Markov chain method, a walking Markov method, a Bayesian method, a long range correlation method, or a change point method.
22. 22. The method of claim 21, wherein the segmentation is performed using a change-point method, the change-point method being a pruned exact linear time (PELT) method.
23. The method of any one of claims 1 to 22, further comprising overlaying the selected copy number grid model and the copy number grid model input data to generate an overlay, and displaying the overlay.
24. 24. The method of claim 23, wherein the overlay is displayed using an electronic display.
25. 25. The method of any one of claims 1 to 24, further comprising calling copy number alterations for the one or more loci or one or more genomic segments based on one or more assigned copy number states or total coverage ratio thresholds.
26. 26. The method of claim 25, wherein the called copy number alterations for the one or more genetic loci or the one or more genomic segments are used to diagnose or confirm a diagnosis of disease in the subject.
27. 26. The method of claim 24 or 25, further comprising generating a genomic profile for the subject comprising the called copy number alterations for the one or more genetic loci or the one or more genomic segments.
28. 28. The method of claim 27, wherein the genomic profile of the subject further comprises results from a comprehensive genomic profiling study, a gene expression profiling study, a cancer hotspot panel study, a DNA methylation study, a DNA fragmentation study, an RNA fragmentation study, or any combination thereof.
29. 29. The method of claim 27 or 28, wherein the genomic profile of the subject further comprises results from a nucleic acid sequencing-based test.
30. 30. The method of any one of claims 27 to 29, further comprising selecting an anti-cancer drug, administering an anti-cancer drug, or administering an anti-cancer treatment to the subject based on the generated genomic profile.
31. 31. The method of any one of claims 25-30, wherein the called copy number alterations for the one or more genetic loci or the one or more genomic segments are used in making suggested treatment decisions for the subject.
32. 32. The method of any one of claims 25 to 31, wherein the called copy number changes for the one or more genetic loci or the one or more genomic segments are used in applying or administering a treatment to the subject.
33. 1. A method for diagnosing a disease, the method comprising:
26. A method comprising determining that a subject has the disease based on called copy number changes for one or more genetic loci or one or more genomic segments, wherein the called copy number changes for the one or more genetic loci or one or more genomic segments are determined according to the method of claim 25.
34. 1. A method of identifying a subject as eligible for a clinical trial for the treatment of a disease, comprising:
26. A method comprising determining that the subject has the disease based on called copy number changes for one or more genetic loci or one or more genomic segments, wherein the called copy number changes for the one or more genetic loci or one or more genomic segments are determined according to the method of claim 25.
35. 35. The method of claim 34, further comprising enrolling the subject in the clinical trial.
36. 36. The method of claim 34 or 35, further comprising administering said treatment to said subject.
37. 37. The method of claim 36, wherein the treatment is an anti-cancer therapy.
38. 38. The method of any one of claims 33 to 37, wherein the disease is cancer, a disease associated with chromosomal aneuploidy, or fragile X.
39. The method according to any one of claims 33 to 37, wherein the disease is cancer.
40. 40. The method of claim 39, further comprising selecting an anti-cancer treatment for administration to the subject based on the called copy number alterations for the one or more genetic loci or the one or more genomic segments.
41. 1. A method for selecting an anti-cancer treatment for a subject having cancer, the method comprising:
26. A method comprising selecting an anti-cancer treatment for the subject in response to copy number alterations for the one or more genetic loci or the one or more genomic segments called according to the method of claim 25.
42. 42. The method of claim 41, further comprising determining an effective amount of an anti-cancer therapy to administer to the subject based on the called copy number changes for the one or more genetic loci or the one or more genomic segments.
43. 43. The method of claim 42, further comprising administering the anti-cancer treatment to the subject based on the called copy number alterations for the one or more genetic loci or the one or more genomic segments.
44. 1. A method of treating cancer in a subject, comprising:
26. A method comprising administering to the subject an effective amount of an anti-cancer therapy in response to called copy number changes for the one or more genetic loci or the one or more genomic segments called according to the method of claim 25.
45. 1. A method for monitoring the progression or recurrence of a tumor in a subject, the method comprising:
26. The method of claim 25, comprising calling copy number alterations for one or more genetic loci or one or more genomic segments using a first sample obtained from the subject at a first time point; calling copy number alterations for one or more genetic loci or one or more genomic segments using a second sample obtained from the subject at a second time point; comparing the first called copy number changes to the second called copy number changes for the one or more genetic loci or the one or more genomic segments, thereby monitoring tumor progression or recurrence.
46. 46. The method of claim 45, wherein the called copy number changes for the one or more loci or one or more genomic segments when using the second sample are determined according to the method of claim 25.
47. 47. The method of claim 45 or 46, further comprising adjusting an anti-cancer therapy in response to the progression of the tumor.
48. 48. The method of any one of claims 45 to 47, further comprising adjusting the dosage of said anti-cancer treatment or selecting a different anti-cancer treatment in response to tumor progression.
49. 49. The method of claim 48, further comprising administering the adjusted anti-cancer therapy to the subject.
50. 50. The method of any one of claims 45-49, wherein the first time point is before the subject is administered an anti-cancer treatment and the second time point is after the subject is administered the anti-cancer treatment.
51. 51. The method of any one of claims 45 to 50, wherein the subject has, is at risk of having, is routinely tested for, or is suspected of having cancer.
52. 52. The method of any one of claims 30-32, 37, 40-44, and 47-51, wherein the anti-cancer treatment comprises chemotherapy, radiation therapy, immunotherapy, targeted therapy, or surgery.
53. 53. The method of any one of claims 38 to 52, wherein the cancer or tumor is a solid cancer.
54. 53. The method of any one of claims 38 to 52, wherein the cancer or tumor is a hematological cancer.
55. The cancer or tumor is B-cell cancer (multiple myeloma), melanoma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, bladder cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small intestine cancer, appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, chondrosarcoma, or blood tissue cancer. , adenocarcinoma, inflammatory myofibroblastoma, gastrointestinal stromal tumor (GIST), colon cancer, multiple myeloma (MM), myelodysplastic syndromes (MDS), myeloproliferative disorders (MPD), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteosarcoma, chordoma, Angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovium, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatic carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealocytoma, hemangioblastoma 55. The method of any one of claims 38 to 54, wherein the cancer is selected from the group consisting of cerebrospinal fluid (CSF), cerebrospinal fluid (CSF), cerebrospinal fluid (CF ...
56. 56. The method of any one of claims 1-55, further comprising generating, by the one or more processors, a report indicating the copy number states or called copy number changes for one or more genomic loci or one or more genomic segments.
57. 57. The method of claim 56, further comprising transmitting the report to the subject or a health care provider.
58. 58. A method according to claim 56 or 57, wherein the report is transmitted over a computer network or a peer-to-peer connection.
59. 59. The method of any one of claims 1 to 58, wherein the subject is suspected of having or determined to have cancer.
60. 60. The method of any one of claims 1 to 59, further comprising obtaining said sample from said subject.
61. 61. The method of any one of claims 1 to 60, wherein the sample comprises a tissue biopsy sample, a liquid biopsy sample, or a normal control.
62. 62. The method of claim 61, wherein the sample is a liquid biopsy sample and comprises blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva.
63. 62. The method of claim 61, wherein the sample is a liquid biopsy sample and comprises circulating tumor cells (CTCs).
64. 62. The method of claim 61 , wherein the sample is a liquid biopsy sample and comprises cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof.
65. 65. The method of any one of claims 1 to 64, wherein the plurality of nucleic acid molecules comprises a mixture of tumor and non-tumor nucleic acid molecules.
66. 66. The method of claim 65, wherein the tumor nucleic acid molecule is derived from a tumor portion of a heterogeneous tissue biopsy sample and the non-tumor nucleic acid molecule is derived from a normal portion of the heterogeneous tissue biopsy sample.
67. 66. The method of claim 65, wherein the sample comprises a liquid biopsy sample, the tumor nucleic acid molecule is derived from a circulating tumor DNA (ctDNA) fraction of the liquid biopsy sample, and the non-tumor nucleic acid molecule is derived from a non-tumor cell-free DNA (cfDNA) fraction of the liquid biopsy sample.
68. 1. A system comprising: one or more processors; and a memory communicatively coupled to the one or more processors and configured to store instructions that, when executed by the one or more processors, cause the system to: receiving, at the one or more processors, sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject; generating minor allele coverage ratios and major allele coverage ratios for a plurality of loci using the one or more processors; segmenting the genome into a plurality of genome segments using the one or more processors; generating, using the one or more processors, copy number grid model input data for loci of the plurality of loci, the copy number grid model input data including (i) a difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio; using the one or more processors to fit a plurality of copy number grid models including allowed copy number states to the copy number grid model input data; selecting a copy number grid model from the plurality of copy number grid models using the one or more processors; and and assigning, using the one or more processors, copy number states for at least a portion of the plurality of genome segments based on the selected copy number grid model.
69. 69. The system of claim 68, wherein the genome is segmented based on the minor allele coverage ratio, the major allele coverage ratio, or a total coverage ratio.
70. The instructions for causing the system to select the selected copy number grid model include: determining a distribution of said copy number grid model input ratio data for each genome segment; identifying, for each genomic segment, the distance between said distribution and a closest copy number state; and determining an overall model fit score based on an average distance across the plurality of genome segments.
71. 71. The system of any one of claims 68-70, wherein different copy number grid models in the plurality of copy number grid models are initialized using different initial tumor purity estimates and tumor ploidy estimates.
72. The instructions to the system to fit allowed copy number states to the copy number grid model input data include: fitting the allowed copy number states to the copy number grid model input data based on an initial tumor purity estimate and an initial tumor ploidy estimate; Iteratively, assigning a spare copy number to each segment of the plurality of segments; determining an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignments; and re-fitting the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate.
73. 73. The system of claim 71 or 72, wherein the initial tumor purity is constrained by a preselected lower tumor purity limit and a preselected upper tumor purity limit.
74. 74. The system of claim 73, wherein the preselected tumor purity lower limit is 0 and the preselected tumor purity upper limit is 1.
75. 75. The system of any one of claims 71-74, wherein the initial tumor ploidy is constrained by a preselected lower tumor ploidy limit.
76. 76. The system of claim 75, wherein the preselected tumor ploidy lower limit is from about 1.1 to about 1.
5.
77. 77. The system of any one of claims 71-76, wherein the initial tumor ploidy is constrained by a preselected upper tumor ploidy limit.
78. 78. The method of claim 77, wherein the preselected upper tumor ploidy limit is from about 6 to about 10.
79. 79. The system of any one of claims 68-78, wherein the assigned copy number state for each of the plurality of genome segments is a total copy number count for the genome segment, a minor allele copy number count for the genome segment, or a major allele copy number count for the genome segment.
80. 80. The system of any one of claims 68-79, wherein the genome is segmented into a plurality of genome segments using a circular binary segmentation (CBS) method, a maximum likelihood method, a hidden Markov chain method, a walking Markov method, a Bayesian method, a long range correlation method, or a change point method.
81. 81. The system of claim 80, wherein the segmentation step is performed using a change-point method, the change-point method being a pruned exact linear time (PELT) method.
82. 82. The system of any one of claims 68 to 81, further comprising an electronic display, said instructions, when executed by the one or more processors, causing the system to overlay the selected copy number grid model and the copy number grid model input data to generate an overlay, and displaying the overlay.
83. 83. The system of any one of claims 68-82, further comprising instructions that, when executed by the one or more processors, cause the system to call copy number alterations for the one or more loci or one or more genomic segments based on one or more assigned copy number states or total coverage ratio thresholds.
84. 84. The system of any one of claims 68-83, further comprising instructions that, when executed by the one or more processors, cause the system to generate a report indicating the copy number states or called copy number changes for one or more genomic loci or one or more genomic segments.
85. 85. The system of claim 84, further comprising instructions that, when executed by the one or more processors, cause the system to transmit the report to the subject or a healthcare provider.
86. 86. A system according to claim 84 or 85, wherein the report is transmitted over a computer network or a peer-to-peer connection.
87. A non-transitory computer-readable storage medium storing one or more programs, the one or more programs including instructions that, when executed by one or more processors of a system, cause the system to: receiving, at the one or more processors, sequence read data for a plurality of sequence reads associated with a plurality of nucleic acid molecules obtained from a sample from a subject; generating minor allele coverage ratios and major allele coverage ratios for a plurality of loci using the one or more processors; segmenting the genome into a plurality of genome segments using the one or more processors; generating, using the one or more processors, copy number grid model input data for loci of the plurality of loci, the copy number grid model input data including (i) a difference between the major allele coverage ratio and the minor allele coverage ratio, and (ii) a sum of the major allele coverage ratio and the minor allele coverage ratio; using the one or more processors to fit a plurality of copy number grid models including allowed copy number states to the copy number grid model input data; selecting, using the one or more processors, a selected copy number grid model from the plurality of copy number grid models; and assigning, using the one or more processors, copy number states for at least a portion of the plurality of genome segments based on the selected copy number grid model.
88. 88. The non-transitory computer readable storage medium of Claim 87, wherein the genome is segmented based on the minor allele coverage ratio, the major allele coverage ratio, or a total coverage ratio.
89. The instructions for causing the system to select the selected copy number grid model include: determining a distribution of the copy number grid model input data for each genome segment; identifying, for each genomic segment, the distance between said distribution and a closest copy number state; and determining an overall model fit score based on an average distance across the plurality of genome segments.
90. 90. The non-transitory computer-readable storage medium of any one of claims 87-89, wherein different copy number grid models in the plurality of copy number grid models are initialized using different initial tumor purity estimates and tumor ploidy estimates.
91. The instructions to the system to fit allowed copy number states to the copy number grid model input data include: fitting the allowed copy number states to the copy number grid model input data based on an initial tumor purity estimate and an initial tumor ploidy estimate; Iteratively, assigning a spare copy number to each segment of the plurality of segments; determining an updated tumor ploidy estimate and an updated tumor purity estimate based on the preliminary copy number assignments; and re-fitting the allowed copy numbers to the copy number grid model input data based on the updated tumor ploidy estimate and the updated tumor purity estimate.
92. 92. The non-transitory computer readable storage medium of claim 90 or 91, wherein the initial tumor purity is constrained by a preselected lower tumor purity limit and a preselected upper tumor purity limit.
93. 93. The non-transitory computer-readable storage medium of claim 92, wherein the preselected tumor purity lower limit is 0 and the preselected tumor purity upper limit is 1.
94. 94. The non-transitory computer readable storage medium of any one of claims 90-93, wherein the initial tumor ploidy is constrained by a preselected tumor ploidy lower limit.
95. 95. The non-transitory computer readable storage medium of claim 94, wherein the preselected tumor ploidy lower limit is from about 1.1 to about 1.
5.
96. 96. The non-transitory computer readable storage medium of any one of claims 90-95, wherein the initial tumor ploidy is constrained by a preselected upper tumor ploidy limit.
97. 97. The non-transitory computer readable storage medium of claim 96, wherein the preselected upper tumor ploidy limit is from about 6 to about 10.
98. 98. The non-transitory computer readable storage medium of any one of claims 87-97, wherein the assigned copy number state is a total copy number count for the genome segment, a minor allele copy number count for the genome segment, or a major allele copy number count for the genome segment.
99. 99. The non-transitory computer readable storage medium of any one of claims 87-98, wherein the genome is segmented into a plurality of genome segments using a circular binary segmentation (CBS) method, a maximum likelihood method, a hidden Markov chain method, a walking Markov method, a Bayesian method, a long range correlation method, or a change point method.
100. 100. The non-transitory computer-readable storage medium of claim 99, wherein the segmentation step is performed using a change-point method, the change-point method being a pruned exact linear time (PELT) method.
101. 101. The non-transitory computer readable storage medium of any one of claims 87 to 100, wherein the system comprises an electronic display, and the instructions, when executed by the one or more processors, further comprise instructions that cause the system to overlay the selected copy number grid model and the copy number grid model input data to generate an overlay, and display the overlay.
102. 102. The non-transitory computer readable storage medium of any one of Claims 87-101, further comprising instructions that, when executed by the one or more processors, cause the system to call copy number alterations for the one or more loci or one or more genomic segments based on one or more assigned copy number states or total coverage ratio thresholds.
103. 102. The non-transitory computer readable storage medium of any one of claims 87-101, further comprising instructions that, when executed by the one or more processors, cause the system to generate a report indicating the copy number states or called copy number changes for one or more genomic loci or one or more genomic segments.
104. 104. The non-transitory computer readable storage medium of claim 103, further comprising instructions that, when executed by the one or more processors, cause the system to transmit the report to the subject or a healthcare provider.
105. 105. The system of claim 103 or 104, wherein the report is transmitted over a computer network or a peer-to-peer connection.
